Yayınlar & Eserler

Yayın Ağı
Makaleler 127
Tümü (127)
SCI-E, SSCI, AHCI (110)
SCI-E, SSCI, AHCI, ESCI (110)
Scopus (116)
TRDizin (18)
Diğer Yayınlar (2)

1. Evaluation of Interleukin-10, Vascular Endothelial Growth Factor Levels, and Bone Marrow Parameters in Multiple Myeloma Patients at Diagnosis and After Treatment

Memis F., Kandefer M. Y., AYDIN S., DALVA K., TOPRAK S. K.
Diagnostics , cilt.15, sa.13, 2025 (SCI-Expanded, Scopus) identifier identifier identifier

2. Impact of PD-1 and PD-L1 expression on treatment outcomes in newly diagnosed acute myeloid leukemia patients

Calis U., Aydogan M., CENGİZ SEVAL G., DALVA K., TOPRAK S. K.
Leukemia Research Reports , cilt.23, 2025 (Scopus) identifier

3. PHENOTYPES OF BONE MARROW MONOCYTES IN HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA: A DESCRIPTIVE PILOT STUDY

Ermis G. Y., DALVA K., Kircali E., Ipek S., Okul N., CENGİZ SEVAL G., et al.
BONE MARROW TRANSPLANTATION , ss.507-508, 2024 (SCI-Expanded, Scopus) identifier

4. In vivo and in vitro effects of cord blood hematopoietic stem and progenitor cell (HSPC) expansion using valproic acid and/or nicotinamide

Gencer E. B., Akin H. Y., TOPRAK S. K., Turasan E., Yousefzadeh M., Yurdakul-Mesutoglu P., et al.
Current Research in Translational Medicine , cilt.72, sa.3, 2024 (SCI-Expanded, Scopus) identifier identifier

5. Common human leucocyte antigensassociated with the development of subacute thyroiditis and COVID-19

Korkmaz F. N., Gökçay Canpolat A., Dalva K., Şahin M., Çorapçıoğlu D.
HUMAN IMMUNOLOGY , cilt.85, sa.4, ss.1-6, 2024 (SCI-Expanded, Scopus) identifier

6. Determination of the Relationship Between the Development and Recurrence of Subacute Thyroiditis and Human Leukocyte Antigen Subtypes

Korkmaz F. N., Gökçay Canpolat A., Dalva K., Elhan A. H., Şahin M., Çorapçıoğlu D., et al.
GENETIC TESTING AND MOLECULAR BIOMARKERS , cilt.28, sa.1, ss.2-9, 2024 (SCI-Expanded, Scopus) identifier identifier identifier

7. Post-induction undetectable flow minimal residual disease ameliorates the high risk determined by FISH among newly diagnosed multiple myeloma

CENGİZ SEVAL G., DALVA K., Bakanay S. M., Soydan E., İLHAN O., BEKSAÇ M., et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , 2023 (SCI-Expanded, Scopus) identifier

8. A Novel Hypothesis: Certain KIR/Cognate Ligand Containing Genotypes Differ in Frequency Among Patients With Myeloma and Have an Effect on Age of Disease Onset

BEKSAÇ M., Akin H. Y., CENGİZ SEVAL G., Yurdakul Mesutoglu P., Anliacik R. G., Anliacik E., et al.
Clinical Lymphoma, Myeloma and Leukemia , cilt.23, sa.5, ss.394, 2023 (SCI-Expanded, Scopus) identifier identifier

9. Role of large unstained cells in predicting successful stem cell collection in autologous stem cell transplantation

Merter M., Sahin U., Uysal S., DALVA K., YÜKSEL M.
Transfusion and Apheresis Science , cilt.62, sa.1, 2023 (SCI-Expanded, Scopus) identifier identifier

10. Two birds with one stone: a Bruton's tyrosine kinase inhibitor in a patient with rheumatoid arthritis and 17p+chronic lymphocytic leukaemia

Sahin Eroglu D., DALVA K., Azap A., Kutlay N., Ates A., Yuksel M.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY , cilt.52, sa.6, ss.703-704, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

11. Effect of CD34⁺ Total/Myeloid CD34⁺ Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation.

DALVA K., Haskologlu S., DALVA AYDEMİR S., ÖZ M. D., ÖZTÜRK BİRGE A., Ipek S., et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation , cilt.20, sa.10, ss.937-944, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

12. A model integrating Killer Immunoglobulin-like Receptor (KIR) haplotypes for risk prediction of COVID-19 clinical disease severity

BEKSAÇ M., Akin H. Y., Gencer-Oncul E. B., Yousefzadeh M., CENGİZ SEVAL G., GÜLTEN E., et al.
Immunogenetics , cilt.73, sa.6, ss.449-458, 2021 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

13. Post-Induction Undetectable Minimal Residual Disease at 10 (-5) Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

Seval G., DALVA K., Oz D., Bakanay S. M., Soydan E., GÜRMAN G., et al.
BLOOD , cilt.138, 2021 (SCI-Expanded, Scopus) identifier

14. Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications

Orgul G., DALVA K., DALVA AYDEMİR S., Alniacik R. G., DÖNMEZ H. G., Cakar A. N., et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY , cilt.148, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

15. Single-Center Study of 72 Patients with Severe Combined Immunodeficiency: Clinical and Laboratory Features and Outcomes

Bayram Ö., Haskologlu S., Bayrakoglu D., Bal S. K., Islamoglu C., Cipe F. E., et al.
JOURNAL OF CLINICAL IMMUNOLOGY , cilt.41, sa.7, ss.1563-1573, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

16. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia

İLHAN O., Narli Ozdemir Z., DALVA K., ARSLAN A., Okay Ozgeyik M., Ipek S., et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY , cilt.43, sa.5, ss.1110-1116, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

17. Long-Term Outcomes of Tamoxifen Citrate Therapy and Histo- And Immunopathological Properties in Riedel Thyroiditis

GÖKÇAY CANPOLAT A., Cinel M., Dizbay Sak S., Taskaldiran I., KORKMAZ H., DEMİR Ö., et al.
European Thyroid Journal , cilt.10, sa.3, ss.248-256, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

18. Prospective Follow-up of Panel Reactive Antibodies From Diagnosis Until Completion of Therapy Including Allogeneic Stem Cell Transplantation Among Patients With Acute Leukemia.

Sahin Eroglu D., Dalva K., Kalaci E., Toprak S. K., Civriz Bozdag S., Topcuoglu P., et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation , 2021 (SCI-Expanded, Scopus) identifier

19. Pleural Involvement Upon Relapse of Myeloma Responding to Daratumumab Plus Carfilzomib: A Case Presentation and Literature Review

Uslu A., CENGİZ SEVAL G., Merter M., DALVA K., BEKSAÇ M.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , cilt.21, sa.3, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

20. A Bottom-Up Proteomic Approach in Bone Marrow Plasma Cells of New-ly Diagnosed Multiple Myeloma Patients

Ayhan B., Turan S. K., Barkan N. P., DALVA K., BEKSAÇ M., Demiralp D. O.
CURRENT PROTEOMICS , cilt.18, sa.5, ss.730-741, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

21. Highlighting the Prognostic Importance of Measurable Residual Disease Among Acute Myeloid Leukemia Risk Factors

Ozdemir Z. N., Sahin U., DALVA K., BALTACI M. A., Uslu A., Ozturk C., et al.
TURKISH JOURNAL OF HEMATOLOGY , cilt.38, sa.2, ss.111-118, 2021 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier identifier

22. The Influence of anti-thymocyte Globulin(ATG) on the Outcomes of Patients with AML W/wo Measurable Residual Disease(MRD) at the time of Unrelated Donor Transplantation

CENGİZ SEVAL G., Kircali E., BALTACI M. A., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.
BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.204, 2020 (SCI-Expanded, Scopus) identifier

23. CD34+Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

Kucukgode G. E., Ipek S., Yildirim Y., Gozukara M. G., DALVA K., CENGİZ SEVAL G., et al.
BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.688-689, 2020 (SCI-Expanded, Scopus) identifier

24. Effect of Desensitization Protocol on Transplantation Success in Children with Anti-HLA Antibodies

Bilir O. A., Bozkaya I. O., Kanbur M. O., Isik M., DALVA K., Adiloglu A. K., et al.
BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.661-662, 2020 (SCI-Expanded, Scopus) identifier

25. Role of Chimerism and flow-cytometric Monitoring of Measurable Residual Disease(MRD) after Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) in Predicting Relapse in Acute Myeloid Leukemia(AML)

CENGİZ SEVAL G., Ulas E. B., TOPRAK S. K., CİVRİZ BOZDAĞ S., Yuksel M. K., TOPÇUOĞLU P., et al.
BONE MARROW TRANSPLANTATION , cilt.55, sa.SUPPL 1, ss.192-193, 2020 (SCI-Expanded, Scopus) identifier

26. Utility investigation of automated techniques in hematopoietic progenitor cell count and viability assessment in the Good Manufacturing Practice (GMP) setting

Kılıç P., Bay M., Baydın P., Şeker Ş., Coşkun Ö., Ülker O. L., et al.
Experimental Biomedical Research , cilt.3, sa.4, ss.231-238, 2020 (TRDizin) Creative Commons License identifier

27. Utility investigation of automated techniques in hematopoietic progenitor cell count and viability assessment in the Good Manufacturing Practice (GMP) setting

KILIÇ P., Bay M., Yıldırım Y., Baydın P., Şeker Ş., Coşkun Ö., et al.
Experimental Biomedical Research , cilt.3, ss.231-238, 2020 (TRDizin) identifier

28. Transferability and curability of allergic disease by allogeneic hematopoietic stem cell transplantation.

Mungan D., GÜRMAN G., Misirligil Z., TOPRAK S. K., DALVA K., TOPÇUOĞLU P., et al.
Allergy , cilt.75, sa.9, ss.2392-2394, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

29. Miyelodisplastik Sendrom HastalarınınAkan Hücre Ölçer ile Yapılan OgataSkorlaması Yoluyla Değerlendirilmesi:Pilot Çalışma

ATİLLA E., Kırcalı E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., et al.
LLM Dergi , cilt.4, sa.3, ss.45-49, 2020 (TRDizin)

30. Evaluation of Patients With Myelodysplastic Syndromeby Ogata Scoring in Flow Cytometry: Pilot Study

ATİLLA E., Kırcalı E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., et al.
LLM Dergi , cilt.4, sa.3, ss.45-49, 2020 (TRDizin)

31. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

Seval G. C., Uslu A., Kircali E., Bozdag S. C., Toprak S. K., Yuksel M. K., et al.
Transplantation and Cellular Therapy , cilt.26, sa.3, ss.305-306, 2020 (SCI-Expanded)

32. Utility investigation of automated techniques in hematopoietic progenitor cell count and viability assessment in the Good Manufacturing Practice (GMP) setting

KILIÇ P., Bay M., BAYDIN P., Şeker Ş., Coşkun Ö., LALEGÜL Ö., et al.
Experimental Biomedical Research , cilt.3, sa.4, ss.231-238, 2020 (TRDizin)

33. İmatinib Tedavisi Alan Hastalarda T Lenfosit Aktivasyonunun Akım Sitometrik Analizi

GÖREN ŞAHİN D., DALVA K., meriç s., GÜRMAN G., ÖZCAN M., ARSLAN Ö., et al.
Osmangazi Tıp Dergisi , 2019 (TRDizin) Creative Commons License

34. A CD34+Cell Enrichment Protocol of Hematopoietic Stem Cells in a Well-Established Quality Management System

Kılıç P., Bay M., Yildirim Y., Coskun Ö., Seker Ş., Baydın P., et al.
CELLS TISSUES ORGANS , cilt.207, sa.1, ss.15-20, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

35. THE EFFECT OF PREDICTED INDIRECTLY RECOGNIZABLE HLA EPITOPES PRESENTED BY HLA-CLASS II MOLECULES ON 1 ANTIGEN/ALELLE MISMATCHED UNRELATED HSCT: A SINGLE CENTER EXPERIENCE

DALVA K., CENGİZ SEVAL G., Oz D., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.
HLA , cilt.93, sa.5, ss.368-369, 2019 (SCI-Expanded, Scopus) identifier

36. Comparison of the methods evaluating post thawing viability of peripheral blood stem cell graft

Varan H. D., Bay M., Ozturk A., DALVA K., İLHAN O.
TRANSFUSION AND APHERESIS SCIENCE , cilt.58, sa.2, ss.192-195, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

37. Hematology Laboratory Survey Reply

Kozanoglu I., Patiroglu T., Dalva K., Demirel G. Y., Soysal T., Demir M.
TURKISH JOURNAL OF HEMATOLOGY , cilt.35, sa.4, ss.304, 2018 (SCI-Expanded, Scopus, TRDizin) identifier

38. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

Topcuoglu P., Cengiz Seval G., Civriz Bozdag S., Toprak S. K., Kurt Yuksel M., Dalva K., et al.
BLOOD , cilt.132, sa.Supplement 1, ss.5776, 2018 (SCI-Expanded, Scopus)

39. Clinical Reflection of Immunophenotyping in Paroxysmal Nocturnal Hemoglobinuria: Experience af a Single Center

ŞAHİN U., MERTER M., NARLI ÖZDEMİR Z., DALVA K., CİVRİZ BOZDAĞ S., YÜKSEL M., et al.
Türkiye'de Lösemi Lenfoma Miyelom Araştırmaları , cilt.2, sa.4, ss.93-97, 2018 (TRDizin)

40. Results of the Hematology Laboratory Survey: What has Changed in Eight Years?

KOZANOĞLU İ., Patiroglu T., DALVA K., YANIKKAYA DEMİREL G., Soysal T., Demir M.
TURKISH JOURNAL OF HEMATOLOGY , cilt.35, sa.3, ss.215-216, 2018 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier

41. Investigating the Presence of Chronic Myeloid Leukemia Leukemic Stem Cells (CML LSCs) in Patients with Tyrosine Kinase Inhibitors Who Achieved Cytogenetic / Molecular Response

NARLI ÖZDEMİR Z., USLU A., TOPRAK S. K., TOPÇUOĞLU P., DALVA K., İLHAN O.
Hematological Disease and Therapies , 2018 (Hakemli Dergi)

42. Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation

Sahin U., DALVA K., Gungor F., Ustun C., BEKSAÇ M.
ANNALS OF HEMATOLOGY , cilt.97, sa.6, ss.1027-1039, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

43. EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF)

Akin H., Yurdakul P., Aydin G., Dalva K., Beksac M.
CYTOTHERAPY , cilt.19, sa.5, 2017 (SCI-Expanded, Scopus) identifier

44. Differential gene expression profiling of human adipose stem cells differentiating into smooth muscle-like cells by TGF beta 1/BMP4

Elçin A. E., Parmaksız M., Dogan A., Seker Ş., Durkut S., Dalva K., et al.
EXPERIMENTAL CELL RESEARCH , cilt.352, sa.2, ss.207-217, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

45. The effect of age on peripheral stem cell mobilization in healthy donors, single center experience

Ozen M., Gunduz M., TOPÇUOĞLU P., TOPRAK S. K., DALVA K., GÜRMAN G., et al.
JOURNAL OF CLINICAL APHERESIS , cilt.32, sa.1, ss.16-20, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

46. Yoğun Kemoterapi Almış RefrakterHematolojik HastalıklardaHaploidentik Kök Hücre NaklininSağkalıma Etkisİ

YÜKSEL M., DALVA K., ŞAHİN U., KURDALOKCU M., KÖKSAL Ö., GÖKMEN A., et al.
LLM DERGİ , 2017 (Hakemli Dergi)

47. Flow Cytometric Aldehyde Dehydrogenase Assay Enables a Fast and Accurate Human Umbilical Cord Blood Hematopoietic Stem Cell Assessment

Gencer E. B., Yurdakul P., DALVA K., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY , cilt.34, sa.4, ss.314-320, 2017 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier

48. Can Burkitt's Lymphoma and Hodgkin's Lymphoma occur in siblings simultaneously?

Kaymak-Cihan M., Kandemir O., DALVA K., Sari N., Kurucu N., Ergurhan-Ilhan I.
TURKISH JOURNAL OF PEDIATRICS , cilt.57, sa.5, ss.536-540, 2015 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier identifier

49. Impact of "Killer Immunoglobulin-Like Receptor/Ligand" Genotypes on Outcome following Surgery among Patients with Colorectal Cancer: Activating KIRs Are Associated with Long-Term Disease Free Survival

Beksac K., BEKSAÇ M., DALVA K., Karaagaoglu E., TIRNAKSIZ M. B.
PLOS ONE , cilt.10, sa.7, 2015 (SCI-Expanded, Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

50. The impact of donor age and sex on the nucleated cell count and CD34 count in healthy bone marrow donors

İNCE E., İLERİ D. T., DOĞU E. F., Ates C., ÇAKMAKLI H. F., DALVA K., et al.
PEDIATRIC TRANSPLANTATION , cilt.19, sa.4, ss.385-390, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

51. HLA Typing with Sequence-Specific Oligonucleotide Primed PCR (PCR-SSO) and Use of the Luminex (TM) Technology

DALVA K., BEKSAÇ M.
BONE MARROW AND STEM CELL TRANSPLANTATION, 2ND EDITION , cilt.1109, ss.87-99, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

52. Comparison of Filgrastim and Lenograstim in Pediatric Solid Tumors

Sari N., DALVA K., Ilhan I. E.
PEDIATRIC HEMATOLOGY AND ONCOLOGY , cilt.30, sa.7, ss.655-661, 2013 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

53. Stem Cell Therapy in Spinal Cord Injury: In Vivo and Postmortem Tracking of Bone Marrow Mononuclear or Mesenchymal Stem Cells

ÖZDEMİR M., ATTAR A., KUZU I., Ayten M., Ozgencil E., BOZKURT M., et al.
STEM CELL REVIEWS AND REPORTS , cilt.8, sa.3, ss.953-962, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

54. Effects of Preoperative Short Term Use of Atorvastatin on Endothelial Progenitor Cells after Coronary Surgery: A Randomized, Controlled Trial

BARAN Ç., Durdu S., DALVA K., Zaim C., Dogan A., OCAKOĞLU G., et al.
STEM CELL REVIEWS AND REPORTS , cilt.8, sa.3, ss.963-971, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

55. Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders

Ross F. M., Avet-Loiseau H., Ameye G., Gutiérrez N. C., Liebisch P., O'Connor S., et al.
Haematologica , cilt.97, sa.8, ss.1272-1277, 2012 (SCI-Expanded, Scopus) identifier identifier

56. HLA-haploidentical transplantations for primary immunodeficiencies: A single-center experience

Cipe F. E., DOĞU E. F., Aytekin C., Yuksek M., KENDİRLİ T., Yildiran A., et al.
PEDIATRIC TRANSPLANTATION , cilt.16, sa.5, ss.451-457, 2012 (SCI-Expanded, Scopus) identifier identifier identifier

57. A FOURIER TRANSFORM INFRARED SPECTROSCOPIC INVESTIGATIONS ON THE MOLECULAR PROFILING OF MULTIPLE MYELOMA

Ayhan B., DALVA K., İPEK S., Ozu D., Ugurbilgin A., ÖZEN M., et al.
HAEMATOLOGICA , cilt.97, ss.592-593, 2012 (SCI-Expanded, Scopus) identifier

58. Flow Cytometric Evaluation of Cell Cycle Regulators (Cyclins and Cyclin-Dependent Kinase Inhibitors) Expressed on Bone Marrow Cells in Patients with Chronic Myeloid Leukemia and Multiple Myeloma

TOPRAK S. K., Dalva K., Cakar M. K., Kursun N., BEKSAÇ M.
TURKISH JOURNAL OF HEMATOLOGY , cilt.29, sa.1, ss.17-27, 2012 (SCI-Expanded, Scopus, TRDizin) identifier identifier

59. Myeloma as a second malignancy following AML: Is a second allo equivalent to auto?

Bakanay S. M., Serbest E., DALVA K., KUZU I., BEKSAÇ M.
Case Reports in Medicine , cilt.2012, 2012 (SCI-Expanded, Scopus) Creative Commons License identifier

60. Immunophenotyping Features in Acute Myeloid Leukemia (AML) with NPM1+ and/or FLT3+

Topcuoglu P., Dalva K., Bozdag S. C., Arslan O., Ozcan M., Ilhan O., et al.
BLOOD , cilt.118, sa.21, ss.4908, 2011 (SCI-Expanded, Scopus)

61. The Shaping of Modern Human Immune Systems by Multiregional Admixture with Archaic Humans

Abi-Rached L., Jobin M. J., Kulkarni S., McWhinnie A., DALVA K., Gragert L., et al.
SCIENCE , cilt.334, sa.6052, ss.89-94, 2011 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

62. CIRCULATING ENDOTHELIAL PROGENITOR CELLS (CEPCS) AFTER RECOMBINANT HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR (RHG-CSF) IN HEALTHY DONORS

TOPÇUOĞLU P., Karacaoglu O., ŞAHİN S., TOPÇUOĞLU P., DALVA K., ARSLAN O.
VOX SANGUINIS , cilt.99, ss.504-505, 2010 (SCI-Expanded, Scopus) identifier

63. Mixed chimerism following hematopoietic stem cell transplantation in pediatric thalassemia major patients: a single center experience

İNCE E., ERTEM M., İLERİ D. T., DALVA K., TOPÇUOĞLU P., Uysal Z.
TURKISH JOURNAL OF HEMATOLOGY , cilt.27, sa.1, ss.8-14, 2010 (SCI-Expanded, Scopus, TRDizin) identifier identifier

64. Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndrome: A Retrospective Validation From a Single Centre.

Topcuoglu P., Dalva K., Bakanay S. M., Bozdag S. C., Arslan O., Ozcan M., et al.
BLOOD , cilt.114, sa.22, ss.4846, 2009 (SCI-Expanded, Scopus)

65. Follow-up of ADAMTS13 enzyme and its relationship with clinical events after allogeneic hematopoietic stem cell transplantation

CİVRİZ BOZDAĞ S., Gunaltay S., DALVA K., ÖZCAN M.
BLOOD COAGULATION & FIBRINOLYSIS , cilt.20, sa.3, ss.165-169, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

66. Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy

Sahin D. G., Dalva K., Meric S., Gurman G., Ozcan M., Arslan O., et al.
BLOOD , cilt.112, sa.11, ss.2633, 2008 (SCI-Expanded, Scopus)

67. The impact of methylenetetrahydrofolate reductase (MTHFR) C677T gene polymorphism on transplant-related variables after allogeneic hematopoietic cell transplantation in patients receiving MTX as GVHD prophylaxis

Soydan E., Topcuoglu P., Dalva K., Arat M.
BONE MARROW TRANSPLANTATION , cilt.42, sa.6, ss.429-430, 2008 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

68. T-helper-1 (Th1) and Th2 cytokines after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

TOPÇUOĞLU P., Bakanay Ş. M., DALVA K., Arat M., BEKSAÇ M., ÖZCAN M.
Turkish Journal of Hematology , cilt.25, sa.1, ss.24-35, 2008 (SCI-Expanded, Scopus, TRDizin) identifier identifier

69. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders

Rawstron A. C., Orfao A., BEKSAÇ M., Bezdickova L., Brooimans R. A., Bumbea H., et al.
HAEMATOLOGICA , cilt.93, sa.3, ss.431-438, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

70. High CD95 expression of BAL lymphocytes predicts chronic course in patients with sarcoidosis

Ozdemir Ö., ÇELİK G., Dalva K., Ulger F., ELHAN A. H., BEKSAÇ M.
RESPIROLOGY , cilt.12, sa.6, ss.869-873, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

71. How to calculate the quantity of CD34+ cells infused? A single center cohort study based on actual, ideal or adjusted ideal body weight

Topcuoglu P., Soydan E. A., Ekiz F., Ayyildiz E., Dalva K., Ozcan M., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.36, sa.3, ss.275-280, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

72. Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra

Soydan E., Ayyildiz E., Dalva K., Topcuoglu P., Tol M., Arslan O., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.36, sa.3, ss.269-273, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

73. Both HLA DRB1*11 and DRB1*15 are observed more frequently among patients with myelodysplastic syndrome compared to healthy controls

Bakanay S. M., Dalva K., Cevirgen T., Bilgin A. U., Beksac M.
LEUKEMIA RESEARCH , cilt.31, 2007 (SCI-Expanded, Scopus) identifier identifier

74. The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD)

Ayyildiz E., Arslan O., Topcuoglu P., Arat M., Dalva K., Soydan E. A., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.36, sa.1, ss.79-85, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

75. Effects of plasma nitric oxide levels on platelet activation in single donor apheresis and random donor concentrates

Buyukkagnici D. I., Ilhan O., Kavas G. O., Arslan O., Arat M., Dalva K., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.36, sa.1, ss.73-78, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

76. Sequence-specific primed PCR (PCR-SSP) typing of HLA Class I and Class II alleles.

DALVA K., BEKSAÇ M.
Methods in molecular medicine , cilt.134, ss.51-60, 2007 (Scopus) identifier identifier

77. HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO)and use of the Luminex technology.

DALVA K., BEKSAÇ M.
Methods in molecular medicine , cilt.134, ss.61-69, 2007 (Scopus) identifier identifier

78. Cytomegalovirus antigenemia is observed more frequently following allogeneic peripheral blood stem cell transplantation compared to bone marrow transplantation

Çelebi H., DALVA K., Özhan M., BEKSAÇ M.
Turkish Journal of Hematology , cilt.23, sa.2, ss.104-110, 2006 (SCI-Expanded, Scopus) identifier

79. Serum transforming growth factor beta 1 levels in multiple myeloma patients

Coşkun H. Ş., Ilham O., ÖZCAN M., Ayaz S., DALVA K., Üstün C., et al.
Turkish Journal of Hematology , cilt.23, sa.1, ss.47-52, 2006 (SCI-Expanded, Scopus) identifier identifier

80. Does continuous flow apheresis influence viability in allogeneic hematopoietic stem cell harvest?

Bakanay S., Dalva K., Arat M., Arslan O., Ayyildiz E., BEKSAÇ M., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.34, sa.2, ss.171-178, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

81. Retrospective validation of an apheresis cycle calculator on autologous PBSC collection in myeloma and malignant lymphoma patients.

Arat M., Soydan E., Cengiz G., Ayyildiz E., Topcuoglu P., Arslan O., et al.
CYTOTHERAPY , cilt.8, 2006 (SCI-Expanded, Scopus) identifier

82. Expression of IFITM1 in chronic myeloid leukemia patients

AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., ÖZBEK U., et al.
LEUKEMIA RESEARCH , cilt.29, sa.3, ss.283-286, 2005 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

83. Allogeneic Hemapoietic Progenitor Cell Collection Using Four Different Cell Separators: A Retrospective Comparative Analysis.

Arat M., Arslan O., Soydan E. A., Ayyildiz E., Dalva K., Tol M., et al.
BLOOD , cilt.104, sa.11, ss.5009, 2004 (SCI-Expanded, Scopus)

84. Both Higher Level of (bcr,abl) Transcripts and High Hasford Risk Score Are Associated with Cytogenetic Response but Absence of Molecular Remission during First Line Use of Imatinib Mesilate(IM): A Finding Not Observed Following Use among Interferon Failures.

Toprak S. K., Dalva K., Mizrak D., Arat M., Ozcan M., Gurman G., et al.
BLOOD , cilt.104, sa.11, ss.4671, 2004 (SCI-Expanded, Scopus)

85. Peripheral blood stem cell apheresis for allogeneic transplants: Ibni Sina experience

Arat M., Arslan O., Ayyildiz E., Topcuoglu P., Dalva K., Han O.
TRANSFUSION AND APHERESIS SCIENCE , cilt.30, sa.3, ss.189-191, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

86. Screening for hemochromatosis in Turkey

Bozkaya H., Bektas M., Metin O., Erkan O., Ibrahimoglu D., Dalva K., et al.
DIGESTIVE DISEASES AND SCIENCES , cilt.49, sa.3, ss.444-449, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

87. The impact of granulocyte colony stimulating factor at content of donor lymphocytes collected for cellular immunotherapy

Arat M., Arslan O., GÜRMAN G., Dalva K., Ozcan M., Ugur A., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.30, sa.1, ss.9-15, 2004 (SCI-Expanded, Scopus) identifier identifier identifier

88. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors

Topcuoglu P., Arat M., Dalva K., Ozcan M.
BONE MARROW TRANSPLANTATION , cilt.33, sa.2, ss.171-176, 2004 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

89. The detection of flow cytometric G-CSF receptor expression and it's effect on therapy in acute myeloid leukemia

Kutlay S., BEKSAÇ M., Dalva K., Ilhan O., Koc H., Akan H., et al.
LEUKEMIA & LYMPHOMA , cilt.44, sa.5, ss.791-795, 2003 (SCI-Expanded) identifier identifier identifier

90. Extramedullary presentation of biclonal IgGκ and IgAκ multiple myeloma

Alanoǧlu G., Özet G., DALVA K., KUZU I., Erekul S., İLHAN O., et al.
Turkish Journal of Haematology , cilt.19, sa.3, ss.421-425, 2002 (SCI-Expanded, Scopus, TRDizin) identifier

91. Monitoring of peripheral blood CD34+cell counts on the first day of apheresis is highly predictive for efficient CD34+cell yield

Demirer T., Ilhan O., Ayli M., Arat M., Dagli M., Ozcan M., et al.
THERAPEUTIC APHERESIS , cilt.6, sa.5, ss.384-389, 2002 (SCI-Expanded) identifier identifier identifier

92. Screening for hemochromatosis in Turkey

Bektas M., Metin O., Erkan O., Turkyilmaz A., Ibrahimoglu D., Nas B., et al.
JOURNAL OF HEPATOLOGY , cilt.36, ss.254-255, 2002 (SCI-Expanded, Scopus) identifier identifier

93. Presence of CMV DNA in blood is a predictor of shorter survival following both allogeneic bone marrow and peripheral stem cell transplantation

Yazman D., Dalva K., Topcuogla P., Soydan E., Baris F., Arat M., et al.
BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded, Scopus) identifier

94. Presence of tissue factor (TF) antigen expressing cells within allogeneic peripheral blood progenitor cell (PBPC) harvest

Ozcan M., Topcuoglu P., Arat M., Dalva K., Soydan E., Arslan O., et al.
BONE MARROW TRANSPLANTATION , cilt.29, 2002 (SCI-Expanded, Scopus) identifier

95. HLA-A1 is associated with CMV viremia in recipients of hematopoietic stem cell transplants from seropositive donors

Dalva K., BEKSAÇ M., Topcuoglu P., Yazman D., Soydan E., Arat M., et al.
TISSUE ANTIGENS , cilt.59, ss.75-76, 2002 (SCI-Expanded) identifier

96. In vivo use of all-trans retinoic acid prior to induction chemotherapy improves complete remission rate and increases rhodamine 123 uptake in patients with de novo acute myeloid leukemia

Ustun C., BEKSAÇ M., Dalva K., Koc H., Konuk N., Ilhan O., et al.
MEDICAL ONCOLOGY , cilt.19, sa.1, ss.59-67, 2002 (SCI-Expanded, Scopus) identifier identifier identifier

97. Probability of finding a HLA identical related bone marrow donor approaches 1:2 in a Turkish registry. Roles of donor bone marrow & cord blood registry and extended family search

DALVA K., Meriç S., GÜVEN N. M., Ikizunal Y., BEKSAÇ M.
European Journal of Immunogenetics , cilt.28, sa.2, ss.358, 2001 (SCI-Expanded, Scopus) identifier

98. Perturbation of p16 and p21 expression is observed in chronic myelogenous leukemia (CML) and multiple myeloma (MM) while cyclins A, B, D and E patterns are generally conserved. A flow cytometric analysis.

TOPRAK S. K., Dalva K., Gultekin G., Topcuoglu P., BEKSAÇ M.
BLOOD , cilt.98, sa.11, 2001 (SCI-Expanded, Scopus) identifier

99. CD41+ and CD42+ hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation

DEMİRER T., Ilhan O., Arat M., YAVUZ Y., ÖZCAN M. E., DALVA K., et al.
Journal of Clinical Apheresis , cilt.16, sa.2, ss.67-73, 2001 (SCI-Expanded, Scopus) identifier identifier

100. Prenatal diagnosis of intrauterine cytomegalovirus infection in a fetus with non-immune hydrops fetalis

Beksac M., Saygan-Karamursel B., Ustacelebi S., Altinok G., Dalva K., Erdinc S., et al.
ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA , cilt.80, sa.8, ss.762-765, 2001 (SCI-Expanded, Scopus) identifier identifier identifier

101. Application of interphase FISH for molecular monitoring of patients transplanted with non-myeloablative conditioning

GÜRMAN G., Arat M., Dalva K., BEKSAÇ M.
BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded, Scopus) identifier

102. Th1/Th2 cytokines and soluble adhesion molecules after allogeneic hematopoietic stem cell transplantation: influence of stem cell source and use of Dalteparin

Celebi H., Ozcan M., Arat M., Dalva K.
BONE MARROW TRANSPLANTATION , cilt.27, 2001 (SCI-Expanded, Scopus) identifier

103. The effect of G-CSF on lymphocyte subsets and CD34+cells in allogeneic stem cell transplantation

GÜRMAN G., Dilek I., Arslan O., Arat M., BEKSAÇ M., Ilhan O., et al.
TRANSFUSION AND APHERESIS SCIENCE , cilt.24, sa.1, ss.23-28, 2001 (SCI-Expanded, Scopus) identifier identifier identifier identifier

104. Effects of combined conventional and modified ultrafiltration in adult patients

Kiziltepe U., Uysalel A., Corapcioglu T., Dalva K., Akan H., Akalin H.
ANNALS OF THORACIC SURGERY , cilt.71, sa.2, ss.684-693, 2001 (SCI-Expanded, Scopus) identifier identifier identifier identifier

105. CD41+and CD42+hematopoietic progenitor cells may predict platelet engraftment after allogeneic peripheral blood stem cell transplantation

Demirer T., Ilhan O., Arat M., Genc Y., Ozcan M., Dalva K., et al.
JOURNAL OF CLINICAL APHERESIS , cilt.16, sa.2, ss.67-73, 2001 (SCI-Expanded, Scopus) identifier

106. Increased telomerase activity (TA) in CD38+CD138+bone marrow mononuclear cells (BMMCs) from multiple myeloma (MM) patients.

BEKSAÇ M., Ma H., Mikail A., Varkey-Altamirano C., Kurt M., Dalva K., et al.
BLOOD , cilt.96, sa.11, 2000 (SCI-Expanded, Scopus) identifier

107. Beneficial effects of iloprost during experimentally induced hemorrhagic shock

Katircioglu S., Ulus A., Gokce P., Apaydin N., Ayaz S., Dalva K., et al.
PANMINERVA MEDICA , cilt.42, sa.2, ss.109-117, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

108. Thrombopoietic cytokines in patients with iron deficiency anemia with or without thrombocytosis

Akan H., Guven N., Aydogdu I., Arat M., BEKSAÇ M., Dalva K.
ACTA HAEMATOLOGICA , cilt.103, sa.3, ss.152-156, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

109. Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant C-CSF

Arslan O., Akan H., Arat M., Dalva K., Ozcan M., GÜRMAN G., et al.
CYTOTHERAPY , cilt.2, sa.4, ss.259-265, 2000 (SCI-Expanded, Scopus) identifier identifier identifier

110. Analysis of tissue factor (TF) expression on leukemic cells by flow cytometry: Correlation with tissue factor activity and clinical parameters

Kilic S., Ozcan M., Dalva K., BEKSAÇ M., Koc H.
THROMBOSIS AND HAEMOSTASIS , ss.763, 1999 (SCI-Expanded, Scopus) identifier

111. Frequencies of HLA DRB1 allel haplotype frequencies in a Turkish registry of bone marrow donors by low resolution typing.

Dalva K., Arat M., Ustun C., Guven N., Meric S., BEKSAÇ M.
BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded, Scopus) identifier

112. Surface adhesion molecules in peripheral stem cells of healthy donors primed with G-CSF.

Akan H., Dalva K., Ustun C., Celebi H., Arat M., BEKSAÇ M., et al.
BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded, Scopus) identifier

113. The influence of CD41+ and CD42+ peripheral blood stem cells on platelet engraftment after allo PBSCT.

Ilhan O., Demirer T., Arat M., Dalva K., COŞKUN H. Ş., BEKSAÇ M., et al.
BONE MARROW TRANSPLANTATION , cilt.23, 1999 (SCI-Expanded, Scopus) identifier

114. Serum transforming growth factor beta 1 levels in multiple myeloma.

COŞKUN H. Ş., Ilhan O., Ozcan M., Ayaz S., Dalva K., Ustun C., et al.
BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus) identifier

115. T-cell subsets in multiple myeloma: Relation to clinical phase and stage of disease and prognosis.

Ates A., Ilhan O., Ozcan M., Dalva K., Ugur N., BEKSAÇ M., et al.
BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus) identifier

116. Effect of in vivo use of alltrans retinoic acid (ATRA) as a single agent on expression of BCL-2 and rhodamine uptake in patients with de novo acute myeloblastic leukemia.

Ustun C., BEKSAÇ M., Dalva K., Konuk N., Koc H., Ilhan O., et al.
BLOOD , cilt.92, sa.10, 1998 (SCI-Expanded, Scopus) identifier

117. HLA tissue status in patients with gluten sensitive enteropathy Gluten enteropatili hastalarda HLA gruplari

Tezel A., Ulker A., ENSARİ A., Baysal C., DALVA K., Dagli U., et al.
Turkish Journal of Gastroenterology , cilt.9, sa.3, ss.269-271, 1998 (Scopus, TRDizin) identifier

118. The characteristics of anti-neutrophyl cytoplasmic antibodies in inflammatory bowel disease Inflamatuvar barsak hastaliklarinda anti-notrofilik sitoplazmik antikorun ozellikleri

Tezel A., Dagli U., Hamzaoglu H., DALVA K., Baysal C., Serin A., et al.
Turkish Journal of Gastroenterology , cilt.8, sa.4, ss.434-439, 1997 (Scopus, TRDizin) identifier

119. The effects of anesthetic agents and surgical techniques on plasma TNF-alpha levels in open cardiac surgery ACIK KALP CERRAHISINDE ANESTEZIK AJAN VE CERRAHI TEKNIKLERIN SERUM TNF-ALFA DUZEYINE OLAN ETKILERI

Durak P., DALVA K., Erdemli O., Ebil S.
Turk Anesteziyoloji ve Reanimasyon , cilt.24, sa.1, ss.24-28, 1996 (Scopus) identifier

120. THE BENEFICIAL-EFFECTS OF AMINOPHYLLINE ADMINISTRATION ON HEPARIN REVERSAL WITH PROTAMINE

KATIRCIOGLU S., KUCUKAKSU D., BOZDAYI M., DALVA K., MAVITAS B., ZORLUTUNA Y., et al.
SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY , cilt.24, sa.2, ss.99-102, 1994 (SCI-Expanded, Scopus) identifier identifier identifier

121. SERUM LEVELS OF CYTOKINES IN CHRONIC VIRAL LIVER-DISEASE

DOLAR M. E., BAYSAL C., DALVA K., CANER M., SAHIN B.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY , cilt.5, sa.11, ss.947-950, 1993 (SCI-Expanded, Scopus) identifier identifier

122. SOLUBLE CD23 AND INTERLEUKIN-2 RECEPTOR LEVELS IN RENAL-ALLOGRAFT RECIPIENTS

BEKSAÇ M., DALVA K., GONENC F., DALVA I., GARIBOGLU S., BATUR N., et al.
TRANSPLANTATION PROCEEDINGS , cilt.25, sa.2, ss.2145-2147, 1993 (SCI-Expanded, Scopus) identifier

123. Thiamine‐responsive megaloblastic anemia with diabetes mellitus and sensorineural deafness

AKINCI A., TEZİÇ T., ERTÜRK G., TARIM Ö., DALVA K.
Pediatrics International , cilt.35, sa.3, ss.262-266, 1993 (Scopus) identifier identifier

124. Soluble CD23 and interleukin-2 receptor levels in renal allograft recipients

Beksac M., DALVA K., Gonenc F., Dalva I., Gariboglu S., Batur N., et al.
Transplantation Proceedings , cilt.25, sa.2, ss.2145-2147, 1993 (Scopus) identifier identifier

125. NONINVASIVE MONITORING OF RENAL-ALLOGRAFT FUNCTIONS

DALVA I., DALVA K., AKBAY E., GUNES Z., AYAZ S., BEKSAÇ M., et al.
KIDNEY INTERNATIONAL , cilt.41, sa.5, ss.1470, 1992 (SCI-Expanded, Scopus) identifier

126. THE EFFECTS OF MIXED LYMPHOCYTE CULTURE ON SHORT AND LONG-TERM SUCCESS OF RENAL-TRANSPLANTATION

BEKSAÇ M., DALVA K., GONENC F., DALVA I., GARIBOGLU S., BATUR N., et al.
KIDNEY INTERNATIONAL , cilt.41, sa.5, ss.1468-1469, 1992 (SCI-Expanded, Scopus) identifier

127. Effect of in vitro hemolysis on 25 common biochemical tests

YÜCEL D., DALVA K.
Clinical Chemistry , cilt.38, sa.4, ss.575-577, 1992 (SCI-Expanded, Scopus) identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 163

1. NÜKS/DİRENÇLİ AKUT MYELOİD LÖSEMİ TEDAVİSİNDE FLAG-İDA İLE KOMBİNE VENETOKLAKS KULLANIMI: TEK MERKEZ DENEYİMİ

KÖKCÜ G., DALVA K., HANEDAR E., SÖNMEZ G. M., BEKTAŞ M., YÜKSEL M., et al.
51.Ulusal Hematoloji kongresi, Türkiye, 28 Ekim - 02 Kasım 2025, (Tam Metin Bildiri)

2. ATG KULLANILAN ALLOJENİK KÖK HÜCRE NAKLİNDE DAHA YÜKSEK TRASPLANTASYON ÖNCESİ LENFOSİT SAYISI SAĞKALIM ORANININ İYİLEŞMESİYLE İLİŞKİLİDİR

KÖKCÜ G., DALVA K., YÜKSEL M., TOPRAK S. K., TOPÇUOĞLU P., ARSLAN Ö., et al.
51.Ulusal Hematoloji kongresi, Türkiye, 28 Ekim - 02 Kasım 2025, (Tam Metin Bildiri)

3. SAÇLI HÜCRELİ LÖSEMİDE KLADRİBİN MONOTERAPİSİNİN UZUN DÖNEM SONUÇLARI VE NÜKSÜ ÖNGÖREN İMMÜNOFENOTİPİK BELİRTEÇLER

BEKTAŞ M., YURDAKUL B. E., DALVA K., ŞAHİN U., CENGİZ SEVAL G., TOPRAK S. K., et al.
51.Ulusal Hematoloji kongresi, Türkiye, 28 Ekim - 02 Kasım 2025, (Tam Metin Bildiri)

4. Prozone effect in flow cytometry in a multiple myeloma patient

Sezen Gökçearslan S., Türkeş G. F., Dalva K., Devrim E.
Bridging Continents to Advance Life Science, 49th FEBS Congress, İstanbul, Türkiye, 5 - 09 Temmuz 2025, ss.330-331, (Özet Bildiri)

5. Aferez Öncesi ve Aferez Ürünü CD34+ Hücre Sayısı/Monosit Oranı Arasındaki İlişki

TÜRKEŞ G. F., DALVA K., ÖZDEMİR T.
KBUD KONGRE LAB&EXPO 2024, Antalya, Türkiye, 18 - 21 Kasım 2024, (Özet Bildiri)

6. Nadir Vaka Çalışması: CD10+ ve CD23+ Tüylü (Saçlı) Hücreli Lösemi

TÜRKEŞ G. F., DALVA K.
KBUD KONGRE LAB&EXPO 2024, Antalya, Türkiye, 18 - 21 Kasım 2024, ss.126, (Tam Metin Bildiri)

7. YENİ TANI AKUT MİYELOİD LÖSEMİ HASTALARINDA PD-1 VE PD-L1 İFADESİNİN TEDAVİ SONUÇLARINA ETKİSİ

ÇALIŞ U., İPEK Ş., OKUL N., DALVA K., TOPRAK S. K.
50. Ulusal Hematoloji Kongresi, 29 Ekim 2024, (Özet Bildiri) Creative Commons License

8. MİKOSİZ FUNGOİDES VE SEZARY SENDROMLU HASTALARDA BRENTUXİMAB VEDOTİN TEDAVİSİNİN UZUN DÖNEM SONUÇLARI

SÖNMEZ G. M., ÖZSAN İ., DÜZ B., ŞANLI H., CENGİZ SEVAL G., DALVA K., et al.
50.Ulusal Hematoloji Kongresi, 29 Ekim - 02 Kasım 2024, (Tam Metin Bildiri)

9. PHENOTYPES OF BONE MARROW MONOCYTES IN HEMATOPOİETİC CELL TRANSPLANTATION FOR ACUTE MYELOİD LEUKEMIA: A DESCRIPTIVE PILOT STUDY

YAVUZ ERMİŞ G., DALVA K., KIRCALI E., İPEK Ş., OKUL N., CENGİZ SEVAL G., et al.
11TH AEGEAN HEMATOLOGY ONCOLOGY SYMPOSIUM, 19 - 22 Eylül 2024, (Tam Metin Bildiri)

10. PHENOTYPES OF BONE MARROW MONOCYTES IN HEMATOPOIETIC CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKEMIA: A DESCRIPTIVE PILOT STUDY

YAVUZ ERMİŞ G., DALVA K., KIRCALI E., İPEK Ş., OKUL N., TOPÇUOĞLU P., et al.
EBMT 2024, İSKOÇYA, 14 - 17 Nisan 2024, (Tam Metin Bildiri)

11. Mononuclear Cell Distribution Analysis From Peripheral Blood As Regards Individual Discrepancies

KILIÇ P., İpek Ş., Coşar B., Yalçın M., Savran N., KORKMAZ F. N., et al.
Sağlık Bilimleri Enstitüsü Uluslararası Sağlık Araştırmaları Kongresi 2022, Ankara, Türkiye, 08 Aralık 2022, (Tam Metin Bildiri)

12. Mononuclear Cell Distribution Analysis in Peripheral Blood as regards Individual Discrepancies

Kılıç P., Ipek Ş., Coşar B., Yalçın M., Savran B. N., Korkmaz F. N., et al.
Uluslararası Sağlık Araştırmaları Kongresi 2022, Ankara, Türkiye, 8 - 09 Aralık 2022, (Özet Bildiri)

13. Novel targets detected by next generation sequencing among triple refractory patients can be clinically targetable

CENGİZ SEVAL G., KUZU I., Yüksel S., YILMAZ H., Yavuz G., KAYGUSUZ G., et al.
19th International Myeloma Society Annual Meeting, 25 Ağustos 2022, (Tam Metin Bildiri) identifier

14. Ex Vivo Epigenetic Modification with Valproic Acid (VPA) Plus Nicotinamide (NAM) Results in Expansion of Umbilical Cord Blood Hematopoietic Progenitors Leading to Faster Engraftment and Chimerism in In Vivo Mouse Xenograft Model

GEncer Öncül E. B., Turasan E., Akın H. Y., YURDAKUL MESUTOĞLU P., SEVAL M. M., ÇAĞAN M., et al.
2022 Tandem Meetings of ASTCTTM and CIBMTR, Amerika Birleşik Devletleri, 23 Nisan 2022, (Tam Metin Bildiri)

15. Ankara Üniversitesi Tıp Fakültesi Doku Tiplendirme Laboratuvarına Anti-HLA Antikorların Taranması ve Antijene Özgün Antikorların Belirlenmesi İçin İletilen Örneklerden Elde Edilen Verilerin Bir Analizi

Dalva K., Öz M. D., Özartam S., Yılmaz F., Bağlan Ö., Aksoy R., et al.
8.Ulusal Transplantasyon İmmunolojisi ve Genetiği Kongresi, Antalya, Türkiye, 14 - 17 Nisan 2022, ss.1-85, (Özet Bildiri) Creative Commons License

16. Organ Nakil Merkezinde Takip Edilen ve Yapılan Çapraz Karşılaştırma Test Sonuçları Pozitif Bulunduğu İçin Bekleme Listesine Alınan Olguların Bir Değerlendirmesi

Aksoy R., Kumru G., Aktar M., Şengül Ş., Keven K., Dalva K.
8. Ulusal Transplantasyon İmmünolojisi ve Genetiği Kongresi, Antalya, Türkiye, 14 - 17 Nisan 2022, ss.27-29, (Özet Bildiri) Creative Commons License

17. QUANTIFICATION OF MRD AT 10-5 BY FLOW IN THE STEM CELL GRAFT CORRELATES WITH MARROW MRD AND PFS FOLLOWING AHCT AMONG PATIENTS DIAGNOSED WITH MM

CENGİZ SEVAL G., DALVA K., ÖZ M. D., GÜRMAN G., İLHAN O., BEKSAÇ M.
48th Annual Meeting of the EBMT, 19 Mart 2022, (Tam Metin Bildiri)

18. İKİNCİ ALLOJENEİK KÖK HÜCRE NAKLİ: GERÇEK YAŞAM VERİSİ

KIRCALI E., CENGİZ SEVAL G., ÖZTÜRK C., YILMAZ H., Yavuz G., Karakaya B., et al.
14. Ulusal kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 10 Mart 2022, (Tam Metin Bildiri)

19. Amniyon Sıvısının, VPA İle Ekspande Hematopoietik Kök Hücre Nakli Sonrası Engrafmana Etkisinin İn Vivo Araştırılması

ÖNCÜL E. B. G., TURASAN E., YOUSEFZADEH M., AKIN H. Y., YURDAKUL MESUTOĞLU P., DALVA K., et al.
14. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Amerika Birleşik Devletleri, 10 Mart 2022, (Tam Metin Bildiri)

20. Post-Induction Undetectable Minimal Residual Disease at 10-5 Sensitivity Level within Marrow and/or Stem Cell Graft Overrides Cytogenetic High Risk

CENGİZ SEVAL G., DALVA K., ÖZ D., BAKANAY S., SOYDAN E., GÜRMAN G., et al.
63rd ASH Annual Meeting and Exposition, Amerika Birleşik Devletleri, 11 Aralık 2021, (Tam Metin Bildiri)

21. Haplotypes rich in activating killer-cell immnuglobulin-like receptor genes are associated with delay on age of myeloma onset

AKIN H., CENGİZ SEVAL G., ATİLLA P., YURDAKUL MESUTOĞLU P., TANER O., ALNIAÇIK R., et al.
18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021, (Tam Metin Bildiri)

22. Postinduction minimal residual disease (MRD) within stem cell graft (gMRD) correlates with marrow MRD (mMRD) and progression free survival (PFS) following autologous stem cell transplantation

CENGİZ SEVAL G., DALVA K., ÖZ M. D., ÖZTÜRK S., SOYDAN E., GÜRMAN G., et al.
18th International Myeloma Workshop, Amerika Birleşik Devletleri, 8 - 11 Eylül 2021, (Tam Metin Bildiri)

23. A prospective analysis on the frequency and predictive value of minimal residual disease assessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance

BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., et al.
23rd Congress of the European Hematology Association, 2021, 14 Haziran 2018, ss.249, (Tam Metin Bildiri)

24. PHENOTYPES OF BONE MARROW MONOCYTES IN STEM CELL TRANSPLANTATION FOR ACUTE LEUKEMIA: A DESCRIPTIVE PILOT STUDY

Yüksel M., Kırcalı E., Öztürk C., Yilmaz H., Koyun D., İpek Ş., et al.
8th International Congress on Leukemia Lymphoma Myeloma, İstanbul, Türkiye, 21 - 22 Mayıs 2021, sa.63, ss.48, (Tam Metin Bildiri)

25. Killer Immunoglobulin-like Haplotype BB is Observed More Frequently Among Myeloma Cases Compared to Healthy Controls

AKIN H. Y., ATACA ATİLLA P., YURDAKUL MESUTOĞLU P., CENGİZ SEVAL G., OTLU T., ALNIAÇIK R., et al.
8th International Congress Leukemia Lymphoma Myeloma (ICLLM), 21 - 22 Mayıs 2021, (Tam Metin Bildiri)

26. Molecular Alterations Obtained by High Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targetted Therapies

KUZU I., SEVAL G. C., YÜKSEL S., Kaygusuz G., DALVA K., ÖZCAN M., et al.
Multiple miyelom AMP kongre 2021, 30 Nisan - 01 Mayıs 2021, (Tam Metin Bildiri)

27. In Vitro Semisolid Agar Veya Sıvı Kültür Koşullarında Vpa Ve Nam Gibi Küçük Moleküller Aracılığı İle Hematopoietik Kök Hücre Ekspansiyonu Kinetikleri

DALVA K., AKIN H. Y., ÖNCÜL E. B. G., TURASAN E., YOUSEFZADEH M., ŞEKER E., et al.
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri)

28. Fare-İnsan Xenograft Hematopoietik Kök Hücre Nakli Modelinde Vpa Ve/Veya Nam İle Ekspande Edilmiş Hematopoietik Kök Hücrelerin Engrafman Kinetikleri

TURASAN E., ÖNCÜL E. B. G., AKIN H. Y., YOUSEFZADEH M., ÇAĞAN M., SEVAL M., et al.
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 02 Nisan 2021, (Tam Metin Bildiri)

29. Yurt İçi Ve Yurt Dışı Gönüllü Akaraba Dışı Vericilerde HLA Özdeşlik Durumu : 10/10 >9/10 Mu Yoksa En Büyük HLADPB1 Mi?

YÜKSEL M., CENGİZ SEVAL G., DALVA K., CEYLAN G., AKAL F., CİVRİZ BOZDAĞ S., et al.
13. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 2 - 03 Nisan 2021, (Tam Metin Bildiri)

30. Phenotypes of Boone Marrow Monocytes in Stem Cell Transplantatio for acute leukemia: A descriptive pilot study

YÜKSEL M., KIRCALI E., ÖZTÜRK C., YİLMAZ H., KOYUN D., ŞENAY İ., et al.
8th International Congress on Leukemia Lymphoma Myeloma, Türkiye, 21 Mayıs 2021, (Tam Metin Bildiri)

31. MM HASTALARINDA TANI SIRASINDA, TEDAVİ SONRASINDA IL-10, VEGF DÜZEYLERİ VE KEMİK İLİĞİNDEKİ PARAMETRELERLE İLİŞKİSİ

CENGİZ SEVAL G., DALVA K., TOPRAK S. K., MEMİŞ F.
42. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020, (Tam Metin Bildiri)

32. AKUT MYELOBLASTİK LÖSEMİ HASTALARINDA NÜKLEOFOSMİN MUTASYONU MİNİMAL REZİDÜEL HASTALIK TAKİBİNDE YOL GÖSTERİCİMİDİR

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.
42.Ulusal Hematoloji Kongresi, Türkiye, 28 - 30 Ekim 2020, (Tam Metin Bildiri)

33. KÖK HÜCRE ÜRÜNÜNDEKİ CD34 HÜCRE ALT GRUPLARI VE ENGRAFMAN İLE İLİŞKİSİ

CENGİZ SEVAL G., TOPÇUOĞLU P., DALVA K., İLHAN O., YÜKSEL M., CİVRİZ BOZDAĞ S., et al.
46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020, (Tam Metin Bildiri)

34. TİROZİN KİNAZ İNHİBİTÖRLERİNİ KESME KARARINDA KEMİKİLİĞİNDEKİ LÖSEMİK KÖK HÜCRE VARLIĞININ ÖNEMİ

İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., et al.
46. Ulusal Hematoloji Kongresi, Türkiye, 28 - 31 Ekim 2020, (Özet Bildiri)

35. CD34+ Cell Subsets in Stem Cell Products and Their Relationship with Engraftment Kinetics

ERTEPE G., İPEK Ş., YILDIRIM Y., GÖZÜKARA M. G., DALVA K., CENGİZ SEVAL G., et al.
46th Annual Meeting of the European Society for Blood and Marrow Transplantation, 29 Ağustos 2020, (Tam Metin Bildiri)

36. The Influence Of Antı-Thymocyte Globulın (Atg) On The Outcomes Of Patıents Wıth Aml W/Wo Measurable Resıdual Dısease (Mrd) At The Tıme Of Unrelated Donor Transplantatıon

CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., YÜKSEL M., KIRCALİ E., BALTACI M. A., TOPÇUOĞLU P., et al.
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

37. Role Of Chımerısm And Flow-Cytometrıc Monıtorıng Of Measurable Resıdualdısease (Mrd) After Allogeneıc Hematopoıetıc Stem Cell Transplantatıon (Allohsct) In Predıctıng Relapse In Acute Myeloıd Leukemıa (AML)

CENGİZ SEVAL G., TOPRAK S. K., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., DALVA K., et al.
46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT, 29 Ağustos - 01 Eylül 2020, (Tam Metin Bildiri)

38. DECISION TO STOP TYROSINE KINASE INHIBITORS (TKIS) WITH BONE MARROW LEUKEMIC STEM CELL LEVEL: DETECTION OF BCR-ABL IN PERIPHERAL BLOOD MAY NOT BE ENOUGH

İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., et al.
25th European Hematology Congress Virtual, 11 - 21 Haziran 2020, (Özet Bildiri)

39. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.
2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, Milan, İtalya, 11 Mayıs - 13 Şubat 2020, cilt.22, ss.35, (Özet Bildiri)

40. Molecular Alterations Obtained by High-Throughput Methods in Multiple Myeloma Patients with Recurrent or Refractory to Heavy Treatment Regimens Could Guide Alternative Targeted Therapies

KUZU I., CENGİZ SEVAL G., YÜKSEL M., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.
2nd AMP Europe Congress on Clinical Genomics - Beyond the Somatic Mutation, 11 - 13 Mayıs 2020, (Tam Metin Bildiri)

41. CD34 VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

CENGİZ SEVAL G., ÖZCAN M., TOPÇUOĞLU P., DEMİRER T., BEKSAÇ M., CİVRİZ BOZDAĞ S., et al.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

42. Hematolojik malignitelerde nakil sonrası hematogon değerlerinin prognoza etkisi var mıdır?

CENGİZ SEVAL G., DALVA K., TOPRAK S. K.
12.Ulusal Kemik iliği transplantasyonu ve hücresel tedaviler kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

43. AKRABA DIŞI VERİCİDEN KHN SÜRECİ BİLEŞENLERİNİN NAKİL ZAMANLAMASINA ETKİSİ: NAKİL ZAMANI DAHA ERKENE ÇEKİLEBİLİR Mİ?

CENGİZ SEVAL G., TOPÇUOĞLU P., BEKSAÇ M., YÜKSEL M., GÜRMAN G., DALVA K., et al.
12.Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 5 - 07 Mart 2020, (Tam Metin Bildiri)

44. CD34+ VE İMMUNEFEKTÖR HÜCRE SAYIMININ TRANSPLANTASYON SONUÇLARINA ETKİSİ

Koyun D., Cengiz Seval G., Dalva K., Uslu A., Öztürk C., Kırcalı E., et al.
12. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Muğla, Türkiye, 5 - 07 Mart 2020, sa.159, ss.60-61, (Tam Metin Bildiri)

45. KIR Genotype and KIR Ligand Phenotypes That Improve the in Vitro Cord Blood or Autologous NK Cell Mediated Cytotoxicity Against Myeloma Marrow Plasma Cells

Akin H. Y., Turasan E., Kircali E., AKKUŞ E., CENGİZ SEVAL G., Yurdakul-Mesutoglu P., et al.
Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, Florida, Amerika Birleşik Devletleri, 19 - 23 Şubat 2020, cilt.26, (Özet Bildiri) identifier

46. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow

CENGİZ SEVAL G., USLU A., KIRCALİ E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.
Transplantation and Cellular Therapy (TCT) Meetings of ASTCT and CIBMTR, 19 - 23 Şubat 2020, (Tam Metin Bildiri)

47. Kronik Myeloid Lösemi (KML) Hastalarında KML Kök Hücresi BCR-ABL’ den Bağımsız Prognostik Bir Faktör Olabilir mi?

İLHAN O., NARLI ÖZDEMİR Z., ARSLAN A., OKAY M., İPEK Ş., DALVA K., et al.
45. Ulusal Hematoloji Kongresi, Türkiye, 30 Ekim - 02 Kasım 2019, (Özet Bildiri)

48. Next Generation Sequencing May be Helpful in Designing Novel Combinations Among Heavily Pretreated Myeloma Patients, Refractory to All Available Approved Anti-Myeloma Drugs

CENGİZ SEVAL G., KUZU I., YÜKSEL S., KAYGUSUZ G., DALVA K., ÖZCAN M., et al.
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier

49. Large Granular Lymphocytosis and Its Impact on Long Term Clinical Outcomes Following Allogeneic Hematopoietic Stem Cell Transplantation: 14-Year Follow-up Data

CENGİZ SEVAL G., Uslu A., Kircali E., CİVRİZ BOZDAĞ S., DALVA K., TOPRAK S. K., et al.
61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Florida, Amerika Birleşik Devletleri, 7 - 10 Aralık 2019, cilt.134, (Özet Bildiri) identifier identifier

50. NGS TUM SECENEKLERİ TUKETMİŞ NUKS VE DİRENCLİ MMHASTALARINDA ENDİKASYON DIŞI TEDAVİ OLUŞTURMADAREHBERLİK EDEBİLİR Mİ?

CENGİZ SEVAL G., KUZU I., YÜKSEL S., DALVA K., ÖZCAN M., BEKSAÇ M.
45. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019, (Özet Bildiri)

51. GENC BİR HASTADA SPLENİK DİFFUZ KIRMIZI PULPA LENFOMA OLGUSU

Kırcalı E., ÖKSÜZ N. E., KUTLAY N., DALVA K., KUZU I., YÜKSEL M.
45 Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 02 Kasım 2019, (Özet Bildiri)

52. KRONİK MİYELOİD LOSEMİ (KML) HASTALARINDA KML KOKHUCRESİ BCR- ABL’DEN BAĞIMSIZ PROGNOSTİK BİR FAKTOR OLABİLİR Mİ?

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.
45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019, (Özet Bildiri)

53. YENİ TANI KLL HASTALARINDA TANI SIRASINDAKİ CD49DEKSPRESYONUNUN HASTALIĞA OZGU BAŞKA PARAMETRELERLEİLİŞKİSİ

TOPRAK S. K., güven m., CENGİZ SEVAL G., DALVA K., İpek Ş., Okul N., et al.
45. ULUSAL HEMATOLOJİ KONGRESİ, Türkiye, 30 Ekim - 02 Kasım 2019, (Özet Bildiri)

54. Tamoxifen citrate could be the drug of choice on the long term follow up of the Riedel thyroiditis

GÖKÇAY CANPOLAT A., CİNEL M., SAK S., TAŞKALDIRAN I., KORKMAZ H., CANLAR Ş., et al.
ETA 2019, 07 Eylül 2019

55. Clonal plasma cell detection by high sensitive flow cytometry in aphaeresis product is poor prognostic and not increased by use of plerixafor alone

CENGİZ SEVAL G., Uslu A., DALVA K., Bakanay S. M., Merter M., Sahin U., et al.
45th Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Frankfurt, Almanya, 24 - 27 Mart 2019, cilt.54, ss.496-497, (Özet Bildiri) identifier

56. The Effect Of Predıcted Indırectly Recognızable Hla Epıtopes Presented By Hla-Class Iı Molecules On 1 Antıgen/Alelle Mısmatched Unrelated Hsct: A Sıngle Center Experıence

DALVA K., CENGİZ SEVAL G., OZ d., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.
HLA, 01 Mayıs 2019, cilt.93, ss.368-369, (Tam Metin Bildiri)

57. Plerixafor, Periferik Kök Hücre Ürününde Akım Sitometri İle Saptanabilen Klonal Plazma Hücre Kontaminasyonunu Etkiler mi?

CENGİZ SEVAL G., USLU A., DALVA K., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., et al.
11. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, Türkiye, 1 - 03 Mart 2019, (Özet Bildiri)

58. Riedel Tiroiditli Hastalarin Klinik, Laboratuar, Patolojik ve Immunolojik Ozelliklerinin Belirlenmesi: Cok merkezli prospektif calisma

GÖKÇAY CANPOLAT A., CİNEL M., TAŞKALDIRAN I., KORKMAZ H., DEMİR Ö., ERSOY R., et al.
8. Türkiye Tiroid Hastalıkları Kongresi, Türkiye, 14 - 15 Aralık 2018

59. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Cente Institution Experience

TOPÇUOĞLU P., CENGİZ SEVAL G., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.
60th ASH Annual Meeting and Exposition, 01 Aralık 2018, (Tam Metin Bildiri)

60. Comparision of Outcomes According to HLA Disparity in Acute Leukemia Patients: A Single Center Institution Experience

TOPÇUOĞLU P., SEVAL G. C., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., DALVA K., et al.
60th ASH Annual Meeting, san diego, Amerika Birleşik Devletleri, 29 Kasım - 05 Aralık 2018, cilt.132, ss.4673, (Tam Metin Bildiri)

61. Kır2ds4’ün Miyelom Plazma Hücrelerine Karşı Otolog Veya Kordon Kanı Doğal Öldürücü Hücre Aracılıklı Toksisitede Rolü

YURDAKUL MESUTOĞLU P., AKIN H., BUNSUZ M., TURASAN E., MERTER M., ÖZTÜRK C., et al.
44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

62. KIR 2DS4 May Influence Autologous and Cord Blood(CB) Natural Killer (NK)Cell Mediated in Vitro Cytotoxicity Against Freshly Isolated Human Bone Marrow Myeloma Plasma Cells and Cell Lines

Mesutoglu P. Y., Akin H. Y., Bunsuz M., Turasan E., Merter M., Ozturk C., et al.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

63. Residual Clonal Plasma Cells Detected By Flow Cytometry at 10(-4)level within Autologous Stem Cell Grafts Is Associated with Significantly Less Overall Survival

CENGİZ SEVAL G., DALVA K., BAKANAY ÖZTÜRK Ş. M., Merter M., Sahin U., Uslu A., et al.
60th Annual Meeting of the American-Society-of-Hematology (ASH), California, Amerika Birleşik Devletleri, 1 - 04 Aralık 2018, cilt.132, (Özet Bildiri) identifier

64. İndüksiyon Mu Hazırlama Rejimi Mi Daha Önemli? İndüksiyon Sonrası Kalıntı Hastalığın Saptanamaması Bir Prognostik Gösterge Olabilir

CENGİZ SEVAL G., BAKANAY ÖZTÜRK Ş. M., MERTER M., ŞAHİN U., USLU A., NARLI ÖZDEMİR Z., et al.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

65. Akut Miyeloid Lösemide Nakil Öncesi ve Nakil Sonrası +28. Gün Değerlendirilen Minimal Kalıntı Hastalığın Hastalık Seyrine Etkisi

DALVA K., NARLI ÖZDEMİR Z., ŞAHİN U., USLU A., MURADOVA B., CENGİZ SEVAL G., et al.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, ss.245-246, (Özet Bildiri)

66. KIR2DS4’ÜN MİYELOM PLAZMA HÜCRELERİNE KARŞIOTOLOG VEYA KORDON KANI DOĞAL ÖLDÜRÜCÜ HÜCREARACILIKLI TOKSİSİTEDE ROLÜ

YURDAKUL MESUTOĞLU P., Akın H. Y., Bunsuz Şengün M., Turasan E., MERTER M., Öztürk C., et al.
44. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

67. Hematopoietik kök hücre nakli için toplanan kemik iliği materyallerinde sayılan cd34 pozitif hücreler: Cd34 pozitif gen hematogonlara dikkat

DALVA K., Öz m. d., hakkoloğlu ş., avcu f., ERTEM M., İLHAN O., et al.
44. ulusal hematoloji kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Tam Metin Bildiri)

68. AKUT LÖSEMİ HASTALARINDA HLA UYUŞUMSUZLUĞUNUNNAKİL SONUÇLARINA ETKİSİ: TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., NARLI ÖZDEMİR Z., TATAR L., SÖKMEN M., CİVRİZ BOZDAĞ S., TOPRAK S. K., et al.
44. Ulusal Hematoloji Kongresi, Türkiye, 31 Ekim - 03 Kasım 2018, (Özet Bildiri)

69. A prospective analysis on the frequency and predictive value of minimal residual disease asessment by flow cytometry and PET-CT imaging among myeloma patients on/off maintenance

BEKSAÇ M., CENGİZ SEVAL G., ŞAHİN U., MERTER M., İPEK Ş., ÖZKAN E., et al.
23rd Congress of European Hematology Association, 14 - 17 Haziran 2018, (Özet Bildiri)

70. Impact Of Mesenchymal Stromal Cells On In Vıtro Growth Of Fresh Human Myeloma Plasma Cells And On Autologous/Cord Blood Nk Cell Medıated Cytotoxıcıty

YURDAKUL MESUTOĞLU P., AKIN H., AYDIN G., SENGUN M., TURASAN E., DALVA K., et al.
ISCT 2018 Annual Meeting, 2 - 05 Mayıs 2018, (Tam Metin Bildiri)

71. A Preliminary Analysis of Inherited Immune Checkpoint Control in Multiple Myeloma: Relative Frequency of Inhibitory or Activating Type Killer Immunoglobulin like Receptors and Their Cognate Ligands HLA-C1 and -C2

BEKSAÇ M., YURDAKUL P., AKIN H., AYDIN G., ŞENGÜN M., ŞAHİN U., et al.
59th American Society of Hematology Annual Meeting, 9 - 12 Aralık 2017, (Özet Bildiri) identifier

72. Multipl miyelomda Killer Immunoglobulin like Reseptörleri (KIR) ve ligandları ile HLA- Grup C1 ve C2'nin sıklığı

BEKSAÇ M., YURDAKUL P., AKIN H. Y., AYDIN G., ŞENGÜN M. B., ŞAHİN U., et al.
43. Ulusal Hematoloji Kongresi, Antalya, Türkiye, 1 - 04 Kasım 2017, (Özet Bildiri)

73. Increased expression of CD24 in Glioblastoma Cell Lines after treatment with Temozolomide and Bortezomib

AKÇORA YILDIZ D., ÖZKAN T., DALVA K., UĞUR H. Ç., SUNGUROĞLU A., Özkanca Ş.
9th Annual Conference onStem Cell and Regenerative Medicine, Berlin, Almanya, 25 - 26 Eylül 2017, (Özet Bildiri)

74. HLA C1/C1 homozygosity decreases relapse rate after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in acute myeloid leukemia (AML) patients

Atilla E., Dalva K., Atilla P. A., TOPRAK S. K., Topcuoglu P., Gulbas Z., et al.
43rd Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation (EBMT), Marseille, Fransa, 26 - 29 Mart 2017, cilt.52, (Özet Bildiri) identifier

75. Isolation and Culture of Good Manufacturing Practice Grade Human Bone Marrow-Derived Mesenchymal Stem Cells for Clinical Applications

ELÇİN A. E., ŞEKER Ş., BAYDIN P., DALVA K., PARMAKSIZ M., LALEGÜL Ö., et al.
BIOMED 2017 (22nd International Symposium on Biomedical Science and Technology), Ankara, Türkiye, 12 - 14 Mayıs 2017, (Özet Bildiri)

76. Isolation And Culture Of Good Manufacturing Practice Grade Human Bone Marrow Derived Mesenchymal Stem Cells For Clinical Applications

ELÇİN A. E., Şeker Ş., BAYDIN P., DALVA K., PARMAKSIZ M., LALEGÜL Ö., et al.
22nd International Symposium on Biomedical Science & Engineering BIOMED, Ankara, Türkiye, 12 Mayıs 2017, (Özet Bildiri)

77. EX VIVO EXPANSION OF HUMAN UMBILICAL CORD BLOOD HEMATOPOIETIC STEM CELLS (HSCS) WITH VALPROIC ACID (VPA) OR NEUROTROPHIC FACTOR (NTF)

Akin H., YURDAKUL P., Aydin G., DALVA K., BEKSAÇ M.
ISCT 2018 MONTREAL ANNUAL MEETING, 2 - 05 Mayıs 2017, cilt.19, ss.83, (Özet Bildiri)

78. MYELODİSPLASTİK SENDROM HASTALARININOGATA SKORLAMASI İLE FLOW SİTOMETRİKOLARAK DEĞERLENDİRİLMESİ

ATİLLA E., ATACA ATİLLA P., TÜREDİ Ö., CİVRİZ BOZDAĞ S., TOPRAK S. K., TOPÇUOĞLU P., et al.
42.Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

79. AKUT MYELOİD LÖSEMİDE FLOW SİTOMETRİ İLEİNDÜKSİYON SONRASI TESPİT EDİLEN CD34 HÜCRESAYISI SAĞKALIM VE RELAPSI ETKİLER

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., TOPRAK S. K., et al.
42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Ekim 2016

80. Myelodisplastik Sendrom Hastalarının OgataSkorlaması ile FlowSitometrik Olarak Değerlendirilmesi

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., TOPRAK S. K., AKAN H., BEKSAÇ M., et al.
ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016, (Özet Bildiri)

81. Akut Myeloid Lösemide Flow SitometriileİndüksiyonSonrasıTespitEdilen CD34 HücreSayısıSağkalımveRelapsıEtkiler

ATİLLA E., ATACA ATİLLA P., CİVRİZ BOZDAĞ S., YÜKSEL M., TOPÇUOĞLU P., ARSLAN Ö., et al.
ULUSAL HEMATOLOJİ 2016, Türkiye, 18 - 22 Ekim 2016

82. Notch Ligandı Fibronektin Valproik Asit Nikotinamid ile Kordon Kanı Kök Hücrelerinin Ex Vivo Ekspansiyonu

Yurdakul P., Gencer E. B., Akin H. Y., DALVA K., KATLAN D. C., BEKSAÇ M. S., et al.
42. Ulusal Hematoloji Kongresi, Türkiye, 19 - 22 Eylül 2016, (Tam Metin Bildiri)

83. IS IT POSSIBLE TO DIAGNOSE LOW RISK MYELODYSPLASTIC SYNDROME (MDS) BY FLOW CYTOMETRY?

Atilla E., Atilla P. A., Turedi O., CİVRİZ BOZDAĞ S., TOPRAK S. K., Akan H., et al.
21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.506, (Özet Bildiri) identifier

84. CD34 POSITIVE CELL COUNT DETECTED BY MULTI-COLOR FLOW CYTOMETRY (MFC) AFTER FIRST INDUCTION THERAPY IN ACUTE MYELOID LEUKEMIA (AML) EFFECTS ON SURVIVAL AND RELAPSE

Atilla E., Atilla P. A., CİVRİZ BOZDAĞ S., YÜKSEL M., Topcuoglu P., Arslan O., et al.
21st Congress of the European-Hematology-Association, Copenhagen, Danimarka, 9 - 12 Haziran 2016, cilt.101, ss.682, (Özet Bildiri) identifier

85. Effects of Donor Recipient KIR Gene Gene Matching on Post Transplant Outcomes in HLA Identical Sibling Hematopoietic Cell Transplantation

ŞAHİN U., DALVA K., GÜNGÖR F., SHANLEY R., ÜSTÜN C., BEKSAÇ M.
3rd International Molecular Immunology & Immunogenetics Congress, Antalya, Türkiye, 27 - 30 Nisan 2016, cilt.4, ss.22, (Özet Bildiri)

86. Expression and in Vitro Binding of Protease Activated Receptor1 (PAR1) with Novel Anti-PAR1 Molecules: Data on Fresh Myeloma Marrow Plasma Cells and Human Myeloma Cell Lines

BEKSAÇ M., Ataca P., Atesagaoglu B., DALVA K., Hidayat A. N., Yalcin I., et al.
57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

87. Comparative Proteomic Analysis of Bone Marrow Plasma Cells By Using Mass Spectrometry Based Bottom up Proteomic Strategies

Beycan A., Demiralp D. F. O., DALVA K., BEKSAÇ M.
57th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 5 - 08 Aralık 2015, cilt.126, (Özet Bildiri) identifier

88. Anti Miyelom için Yeni Bir Hedef Proteaz Aktive Reseptör 1 PAR1 in Myelom Plazma Hücrelerinde ve İnsan Myelom Hücre Dizilerinde İfadesi ve PAR1 Bağlayan Yeni Moleküllerin in vitro Etkileri

ATACA P., ERTAN BOLELLİ T., ÖZKAN T., DALVA K., AKI YALÇIN E. E., YALÇIN İ., et al.
41. Ulusal Hematoloji Kongresi, Türkiye, 21 - 24 Ekim 2015

89. Follow up of del 5 q MDS patients with or without other chromosomal abnormalities

TÜREDİ Ö., ATACA P., TUNCALI T., ATİLLA E., VİCDAN N. A., DURMAZ C. D., et al.
10th European Cytogenetics Conference, 4 - 07 Temmuz 2015, ss.102, (Özet Bildiri)

90. CML leukemic stem cell CML LCS Its existence in patients who achieved cytogenetic molecular response under treatment of TKI

İLHAN O., USLU A., TOPRAK S. K., TOPÇUOĞLU P., ATİLLA E., ATACA P., et al.
ASCO 2015, 29 - 02 Mayıs 2015

91. CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.

Ilhan O., Uslu A., TOPRAK S. K., Topcuoglu P., Atilla E., Ataca P., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

92. HLA TYPING OF A MULTITRANSFUSED SCID PATIENT: WHAT NGS CAN TELL US?

DALVA K., van de Pasch L., Topdagi D., Karagozlu S., Adema J., Aydincak H., et al.
European-Federation-for-Immunogenetics Conference, Geneva, İsviçre, 26 - 29 Nisan 2015, cilt.85, ss.380, (Özet Bildiri) identifier

93. allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Single Centre Experienc

ŞAHİN U., MERTER M., ATİLLA E., TOPÇUOĞLU P., TOPRAK S. K., İLHAN O., et al.
BONE MARROW TRANSPLANTATION, 22 - 25 Mart 2015

94. ALOGENEİC STEM CELL TRANSPLANTATION IN ADULT PATIENTS WITHPAROXYSMAL NOCTURNAL HEMOGLOBINURIA SINGLE CENTER EXPERIENCE

MERTER M., ŞAHİN U., ATİLLA E., CİVRİZ BOZDAĞ S., TOPRAK S. K., YÜKSEL M., et al.
41.EBMT MEETING, 24 - 26 Mart 2015

95. Are there any optimal cell doses for graft repopulation in the Bone Marrow-Derived Allogeneic Hematopoietic Stem Cell Transplantations?

Ataca P., Atilla E., Altas U., Bay M., Dalva K., CİVRİZ BOZDAĞ S., et al.
41st Annual Meeting of the European-Society-for-Blood-and-Marrow-Transplantation, İstanbul, Türkiye, 22 - 25 Mart 2015, cilt.50, (Özet Bildiri) identifier

96. Identification of Genes in Wnt Signaling Pathway with DNA Microarray Analysis in Acute Myeloid Leukemia.

Altınok Güneş B., Özkan T., Karadağ A., Özkeserli Z., Dalva K., Sayınalp N., et al.
FEBS-EMBO, Paris, Fransa, 30 Ağustos - 04 Eylül 2014, ss.219, (Özet Bildiri)

97. AKRABA DIŞI ALLOJENEİK HEMATOPOETİK HÜCRE NAKLİNDE HLA UYUŞUMUNUN ETKİSİ-TEK MERKEZ DENEYİMİ

CENGİZ SEVAL G., TOPÇUOĞLU P., ÖZEN M., GÜNDÜZ M., ATİLLA E., DALVA K., et al.
8. Ulusal Kemik İliği Transplantasyonu ve Hücresel Tedaviler Kongresi, 06 Mart 2014, (Özet Bildiri)

98. Chemosensitivity to Induction or High Dose Therapy, Pre/Post Transplant PET Negativity and Absence of Minimal Residual Disease within Mobilized Stem Cell Graft Predict Long Term Disease Free Survival in Multiple Myeloma

Bakanay S. M., DALVA K., KÖKSOY E. B., Civit D., Ayyildiz E., ÖZCAN M., et al.
BMT Tandem Meetings, Texas, Amerika Birleşik Devletleri, 26 Şubat - 02 Mart 2014, cilt.20, (Özet Bildiri) Creative Commons License identifier

99. Preliminary Results Of A Mass Spectrometry Based Bottom Up Proteomic Approach On Bone Marrow Plasma Cells From Patients With Multiple Myeloma (MM)

Ayhan B., Demiralp D. O., Dalva K., Beksac M.
55th Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 7 - 10 Aralık 2013, cilt.122, (Özet Bildiri) identifier

100. Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers

Suyani E., Bakanay S. M., DALVA K., Cakmak E., Haznedar R., Sncak G., et al.
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2012, cilt.120, (Özet Bildiri) identifier

101. Minimal Residual Plasma Cell Content of Autulogous Grafts, Chemosensitivity to Induction or High Dose Therapy and Pre/Post Transplant PET Negativity Predict Long Term Disease Free Survival in Multiple Myeloma.

Bakanay S. M., Dalva K., Koksoy B. E., Ayyildiz E., ÖZCAN M., İLHAN O., et al.
54th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Georgia, Amerika Birleşik Devletleri, 8 - 11 Aralık 2012, cilt.120, (Özet Bildiri) identifier

102. A case with therapy-related myelodysplastic syndrome secondary to acute myeloid leukemia

Kaymak Cihan m., Yıldırım Ü. M., Paç A., Gül S., Duman R., Tekgündüz E., et al.
VI. International Symposium on Myelodysplastic Syndrome and Bone Marrow Failures in Childhood, 23 - 26 Haziran 2012, (Özet Bildiri)

103. The effect of cyclophosphamide with bortezomib as the mobilisation regimen on the graft quality and response of disease in multiple myeloma

Topcuoglu P., Baslar S., CİVRİZ BOZDAĞ S., Dalva K., Ayyildiz E., Uysal A., et al.
38th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation (EBMT), Geneva, İsviçre, 1 - 04 Nisan 2012, cilt.47, (Özet Bildiri) identifier

104. AML’de CD34+ Hematopoetik Kök Hücrelerde Wnt Sinyal Yolağındaki Genlerin DNA Mikroarray Analizi ile Tanımlanması.

Altınok Güneş B., Özkan T., Karadağ A., Özkeserli Z., Dalva K., Beksaç M., et al.
XII. Ulusal Tıbbi Biyoloji ve Genetik Kongresi , Antalya, Türkiye, 27 - 30 Ekim 2011, ss.51, (Özet Bildiri)

105. Peripheral stem cell apheresis in multiple myeloma in the era of new agents

Bakanay S. M., Ayyildiz E., Arat M., Topcuoglu P., Soydan E., Dalva K., et al.
37th European Group for Bone and Marrow Transplantation/27th Meeting of the EBMT Nurses Group/10th Meeting of the EBMT Management Group, Paris, Fransa, 3 - 06 Nisan 2011, cilt.46, (Özet Bildiri) identifier

106. Effects of Atorvastatin Pretreatment on Endothelial Progenitors Cells After Coronary Surgery: A Randomized, Controlled Trial

BARAN Ç., AKAR A. R., aslan ö., DURDU M. S., DALVA K., ZAİM Ç., et al.
STS 47TH ANNUAL MEETING, SAN DIEGO, Amerika Birleşik Devletleri, 31 Ocak - 02 Şubat 2011, (Özet Bildiri)

107. Comparison of the most frequent haplotypes of Turkish subjects in two registries: TRAN and DKMS

BEKSAÇ M., Dalva K.
24th European Immunogenetics and Histocompatibility Conference/17th Annual Meeting of the Italian-Society-for-Immunogenetics-and-Transplantation-Biology, Florence, İtalya, 15 - 18 Mayıs 2010, cilt.75, ss.509, (Özet Bildiri) identifier

108. Significance of serial chimerism analysis in allogeneic haematopoietic cell transplantation for bone marrow failure: do stable mixed chimerism matter?

Bakanay S. M., Arat M., Serbest E., Topcuoglu P., Soydan E. A., Bilgin A. U., et al.
36th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantat/9th Meeting of the EBMT Data-Management-Group/26th Meeting of the EBMT Nurses Group/2nd EBMT Qual Management Meeting, Vienna, Avusturya, 21 - 24 Mart 2010, cilt.45, (Özet Bildiri) identifier

109. TRACKING OF DONOR TYPE GREN FLUORESCENT AND LUCIFERASE POSITIVE MARROW MONONUCLEAR OR MESENCHYMAL STEM CELLS IN POSTMORTEM SPINAL CORD HISTOPATHOLOGICAL SECTIONS FOR DETERMINATION OF REGENERATION IN A SPINAL CORD INJURY MODEL

Beksac M., Kuzu I., Ozdemir M., Ayten M., Dalva K., Uckan D., et al.
14th Annual Meeting of the European-Hematology-Association, Berlin, Almanya, 4 - 07 Haziran 2009, ss.66, (Özet Bildiri) identifier

110. HLA specificities/haplotypes of patients who have no matched donors available worldwide: a report from TRAN-Turkey

DALVA K., Akal F., Basalp A., Uguz E., BEKSAÇ M.
23rd European Immunogenetics and Histocompatibility Conference, Ulm, Almanya, 9 - 12 Mayıs 2009, cilt.73, ss.451-452, (Özet Bildiri) identifier

111. Results from satellite workshop on molecular chimerism quantification after allogenic stem cell transplantation

Alizadeh M., Moine A., Constantinescu A. D., Balas A., Mazzi B., Porfirio B., et al.
23rd European Immunogenetics and Histocompatibility Conference, Ulm, Almanya, 9 - 12 Mayıs 2009, cilt.73, ss.395-396, (Özet Bildiri) identifier

112. Flow Cytometric Analysis of T Cell Functions in CML Patients Under Imatinib Therapy.

Sahin D. G., DALVA K., Meric S., GÜRMAN G., ÖZCAN M., ARSLAN Ö., et al.
50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.911, (Özet Bildiri) identifier

113. COMPARATIVE ANALYSIS OF MESENCHYMAL STEM CELL CONTENT DETECTED BY FLOW CYTOMETRY IN UMBILICAL CORD BLOOD, G-CSF MOBILIZED PERIPHERAL BLOOD, ADULT AND PEDIATRIC BONE MARROW OF HEALTHY DONORS

Beksac M., Ersoy H. E., Dalva K., Uckan D. U., Meric S. M., Beksac M. S. B., et al.
13th Congress of the European-Hematology-Association, Copenhagen, Danimarka, 12 - 15 Haziran 2008, cilt.93, ss.524-525, (Özet Bildiri) identifier

114. FACTORS INVOLVED IN RESPONSE TO THALIDOMIDE IN MYELODYSPLASTIC SYNDROME: IMPACT OF HLA AND PROGNOSTIC FACTORS

Bakanay S. M., Dalva K., Topcuoglu P., Bozdag-Civriz S., BEKSAÇ M., GÜRMAN G.
13th Congress of the European-Hematology-Association, Copenhagen, Danimarka, 12 - 15 Haziran 2008, cilt.93, ss.406-407, (Özet Bildiri) identifier

115. HLA-A, -B, -C, -DR haplotypes, linkeage and frequencies observed in Ankara University, Turkey: a report from Tran

BEKSAÇ M., Dalva K.
22nd European Immunogenetics and Histocompatibility Conference, Toulouse, Fransa, 2 - 05 Nisan 2008, cilt.71, ss.373, (Özet Bildiri) identifier

116. The presence of thrombophilia and the development of thromboembolic complications in allogeneic haematopoietic cell transplantation

Topcuoglu P., Gunaltay S., Dalva K., Bilgin A. U., Arat M., GÜRMAN G., et al.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41, (Özet Bildiri) identifier

117. The relation between the disparities of short tandem repeats between donor-recipient pair and the allogeneic haematopoietic cell transplantation outcome

Serbest E., Topcuoglu P., Dalva K., Bilgin A. U., Soydan E., Ozcan M., et al.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41, (Özet Bildiri) identifier

118. Do the febrile neutropenic episodes during mobilisation have any effect on autologous stem cell collection yield in patients with myeloma and lymphoma?

Topcuoglu P., Bilgin A. U., Ayyildiz E., Dalva K., Arslan O., Ilhan O., et al.
34th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/24nd Meeting of the EBMT-Nurses-Group/7th Meeting of the EBMT-Data-Management-Group, Florence, İtalya, 30 Mart - 02 Nisan 2008, cilt.41, (Özet Bildiri) identifier

119. THE IMPACT OF THE DISPARITIES OF SHORT TANDEM REPEATS (STR) BETWEEN DOONOR-RECIPIENT PAIR ON THE ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT) OUTCOME

Serbest E., Topcuoglu P., Dalva K., Bilgin A. U., Soydan E. A., Ozcan M., et al.
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, Amerika Birleşik Devletleri, 13 - 17 Şubat 2008, cilt.14, ss.111-112, (Özet Bildiri) identifier

120. THE RELATION BETWEEN THE FREQUENCY OF PRESENCE OF THROMBOPHILIA AND THROMBOEMBOLIC COMPLICATIONS AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (AHCT)

Topcuoglu P., Gunaltay S., Dalva K., Bilgin A. U., Arat M., Ozcan M.
Annual Meeting of the American-Society-for-Blood-and-Marrow-Transplantation, California, Amerika Birleşik Devletleri, 13 - 17 Şubat 2008, cilt.14, ss.111, (Özet Bildiri) identifier

121. Dna hyperploidy is associated with both high plasma cell percentage & high beta 2 microglobulin and impairs survival in myeloma patientstreated with or without transplantation

Dalva K., Soydan E. A., Kizil M., Topcuoglu R., Gungor F., ATASOY B. M., et al.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.402-403, (Özet Bildiri) identifier

122. The determination of leukemic phenotype and minimal residual disease in acute myeloid leukemia by using flow cytometry

Topcuoglu P., Dalva K., Meric S., Sahin S., Arat M., BEKSAÇ M.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.19, (Özet Bildiri) identifier

123. Impact of HLA on availability of a donor, graft versus host disease frequency, and survival among 611 myeloma patients transplanted at three institutions from three continents

BEKSAÇ M., Garcia Sanz R., Dalva K., Gungor F., Cevirgen T., Alcoceba M., et al.
11th International Myeloma Workshop/4th International Workshop on Wladenestroms Macroglobulinemia, Kos Isl, Yunanistan, 25 - 30 Haziran 2007, cilt.92, ss.185, (Özet Bildiri) identifier

124. The impact of disparity in short tandem repeats (STRS) analysis on the outcome of allogeneic hematopoietic cell transplantation (allo-HCT) from HLA-identical sibling donors

Serbest E., Topcuoglu P., Dalva K., Soydan E. S., Arslan O. A., Ozcan M. O., et al.
12th Congress of the European-Hematology-Association, Vienna, Avusturya, 7 - 10 Haziran 2007, cilt.92, ss.517, (Özet Bildiri) identifier

125. HLA-DR15 and HLA-DR3 are observed more frequently among allo-transplanted compared to auto-transplanted or non-transplanted patients, a finding observed in myeloma, but not CML, cases from various countries

BEKSAÇ M., Dalva K., Stockerl-Goldstein K., Sanz R. G., Hungria V. T., Cevirgen T., et al.
21st European Immunogenetics and Histocompatibility Conference, Barcelona, İspanya, 5 - 08 Mayıs 2007, cilt.69, ss.514, (Özet Bildiri) identifier

126. HemHLA (R) (Ankara, tr): a flexible software for HLA typing laboratories and registries that supports storage, transport and search functions on donor/recipient data

Dalva K., Tuertekin M., Gueclue O., BEKSAÇ M.
21st European Immunogenetics and Histocompatibility Conference, Barcelona, İspanya, 5 - 08 Mayıs 2007, cilt.69, ss.529-530, (Özet Bildiri) identifier

127. Relationship between the mucositis seen after the allogeneic haematopoietic stem cell transplantation and the human leucocyte antigen types

Kabacam G., Soydan E. A., Topcuoglu P., Dalva K., Ozdemir P., Ozcan M.
33rd Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation, Lyon, Fransa, 25 - 28 Mart 2007, cilt.39, (Özet Bildiri) identifier

128. MULTİPL MİYELOMA VE MALİN LENFOMALI HASTALARDA OTOLOG PERİFERİK KÖK HÜCRE TOPLANMASINDA AFEREZ GÜN SAYISI ÖNGÖRÜLEBİLİR Mİ? - ANKARA HESAPLAMA FORMÜLÜ

ARAT M., CENGİZ SEVAL G., SOYDAN E., AYYILDIZ E., TOPÇUOĞLU P., ARSLAN Ö., et al.
32. Ulusal Hematoloji Kongresi, 08 Kasım 2006, (Tam Metin Bildiri)

129. Two independent effects of immunoglobulin-like receptor (KIR) allele matching between siblings: Inhibitory KIR (iKIR) mismatches are associated with graft versus host disease (GVHD) while activatory KIR matches (aKIR) and cGVHD are associated with graft versus leukemia (GVL).

Dalva K., Gungor F., Akcaglayan E. S., BEKSAÇ M.
48th Annual Meeting of the American-Society-of-Hematology, Florida, Amerika Birleşik Devletleri, 9 - 12 Aralık 2006, cilt.108, (Özet Bildiri) identifier

130. bcr,abl fusion binding HLA molecule frequencies among patients with CML

Dalva K., Guven N., Sebest E., Cevirgen T., BEKSAÇ M., Ilhan O.
32nd Annual Meeting of the American-Society-for-Histocompatibility-and-Immunogenetics, California, Amerika Birleşik Devletleri, 16 - 20 Ekim 2006, cilt.67, (Özet Bildiri) identifier

131. Class I and II antigens that are associated with rate or age at presentation of multiple myeloma: Preliminary results from two centers in Turkey

Cevirgen T., Dalva K., Akcaglayan E. S., Arslan U., Ersoy F., BEKSAÇ M.
20th European Immunogenetics and Histocompatibility Conference, Oslo, Norveç, 8 - 11 Haziran 2006, cilt.67, ss.547-548, (Özet Bildiri) identifier

132. Role of killer inhibitory receptor (KIR) allele and ligand mismatches (mm) in HLA identical sibling haematopoetic stem cell transplants

Gungor E., Dalva K., Akcaglayan E. S., Oztuna D., BEKSAÇ M.
20th European Immunogenetics and Histocompatibility Conference, Oslo, Norveç, 8 - 11 Haziran 2006, ss.502, (Özet Bildiri) identifier

133. Follow-up of ADAMTS13 Enzyme and its relationship with clinical events after allogeneic haematopoietic stem cell transplantation

CİVRİZ BOZDAĞ S., Gunaltay S., Dalva K., Ozcan M.
32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, Hamburg, Almanya, 19 - 22 Mart 2006, cilt.37, (Özet Bildiri) identifier

134. HLA B51-DR04 phenotype which is an infrequent observation in multiple myeloma may be associated with longer disease-free survival: preliminary results from two centres in Turkey

Dalva K., Cevirgen T., Soydan E., Ersoy F., BEKSAÇ M.
32nd Annual Meeting of the European-Group-for-Blood-and-Morrow-Transplantation/22nd Meeting of the EBMT-Nures-Group/5th Meeting of the EMBT-Data-Management-Group, Hamburg, Almanya, 19 - 22 Mart 2006, cilt.37, (Özet Bildiri) identifier

135. A new predictive and prognostic marker for de novo AML: Peripheral blood CD34 (pCD34) count at recovery following remission induction (RI) therapy (Supp. by Ankara university2003-0809114).

Arat M., Topcuoglu P., YÜKSEL M., Dalva K., Gultekin G., GÜRMAN G., et al.
47th Annual Meeting of the American-Society-of-Hematology, Georgia, Amerika Birleşik Devletleri, 10 - 13 Aralık 2005, cilt.106, (Özet Bildiri) identifier

136. Impact of harvest product volume in erythrocyte depletion of allogeneic or autologous bone marrow using COBE spectra

SOYDAN e., AYYILDIZ E., DALVA K., TOPÇUOĞLU P., TOL M., ARSLAN Ö., et al.
15th Congress of the Interdisciplinary-European-Society-for-Haemapheresis-and-Haemotherapy, 5 - 09 Ekim 2005, (Özet Bildiri)

137. Interleukin-10(IL-10)1082-A and tumor necrosis factor(TNF)alpha 238/308A genotypes are associated with earlier (younger than 55) onset of multiple myeloma

BEKSAÇ M., Kizil M., Soydan E., Serbest E., Dalva K.
19th European Immunogenetics and Histocompatibility Conference, İstanbul, Türkiye, 23 - 26 Nisan 2005, cilt.6, (Özet Bildiri) identifier

138. BCR,ABL fusion binding HLA molecule frequencies among patients with civil

Dalva K., Serbest E., Gungor F., Akfirat H., BEKSAÇ M.
19th European Immunogenetics and Histocompatibility Conference, İstanbul, Türkiye, 23 - 26 Nisan 2005, cilt.6, (Özet Bildiri) identifier

139. Evaluation of thrombophilia associated genetic mutations, coagulometric and immunological parameters in menopausal patients.

Mollamahmutoglu S., Dalva K., Beksac S.
52nd Annual Meeting of the Society-for-Gynecologic-Investigation, Los-Angeles, Şili, 23 - 26 Mart 2005, cilt.12, (Özet Bildiri) identifier

140. Both higher level of (bcr,abl) transcripts and high Hasford risk score are associated with cytogenetic response but absence of molecular remission during first line use of imatinib mesilate(IM): A finding not observed following use among interferon failures.

TOPRAK S. K., Dalva K., Mizrak D., Arat M., Ozcan M., GÜRMAN G., et al.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

141. Interleukin-10(IL-10)1082-A and tumor necrosis factor(TNF)-Alpha 238/308A genotypes are associated with earlier (Younger than 55) onset of multiple myeloma.

BEKSAÇ M., Kizil M., Soydan E., Serbest E., Dalva K.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

142. Allogeneic hemapoietic progenitor cell collection using four different cell separators: A retrospective comparative analysis.

Arat M., Arslan O., Soydan E., Ayyildiz E., Dalva K., Tol M., et al.
46th Annual Meeting of the American-Society-of-Hematology, California, Amerika Birleşik Devletleri, 4 - 07 Aralık 2004, cilt.104, (Özet Bildiri) identifier

143. A comparison of the number of informative short tandem repeat (STR) loci between HLA identical donor-recipient pairs and the frequency of graft versus host disease (GVHD)

Dalva K., Arat M., Serbest E., BEKSAÇ M.
18th European Histocompatibility Conference, Sofija, Bulgaristan, 8 - 11 Mayıs 2004, cilt.5, (Özet Bildiri) identifier

144. Apoptosis in the haematopoietic stem cell products obtained by continuous flow apheresis method in allogeneic peripheral stem cell transplantation

Bakanay S., Arat M., Dalva K., Arslan O., BEKSAÇ M., Ayyildiz E., et al.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

145. Occurrence of cytomegalovirus infection and/or viraemia shortens overall survival

Topcuoglu P., Arat M., Soydan E., Dalva K., Ciftcioglu A., Akan H., et al.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

146. A comparison of the number of informative short tandem repeat loci between HLA identical donor-recipient pairs and the frequency of graft-versus-host disease

Dalva K., Arat M., Serbest E., BEKSAÇ M.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

147. The impact of HLA-dr antigens on chronic graft-versus-host disease associated oral lichenoid lesions

Sanli H., Ozdemir E., Arat M., Ekmekci P., Dalva K., BEKSAÇ M.
30th Annual Meeting of the European-Group-for-Blood-and-Marrow-Transplantation/20th Meeting of the EBMT-Nurses-Group/3rd Meeting of the EBMT-Data-Management-Group, Barcelona, İspanya, 28 - 31 Mart 2004, cilt.33, (Özet Bildiri) identifier

148. Tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), interleukin-10 (IL-10), transforming growth factor-beta (TGF-beta) and interferon-gamma (INF-gamma) polymorphic single nucleotide allele frequencies in patients with multiple myeloma (MM): Disparities between the siblings and effect on treatment outcome.

BEKSAÇ M., Kizil M., Soydan E., Serbest E., AKYERLİ BOYLU C., Ozcelik T., et al.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102, (Özet Bildiri) identifier

149. Fetal-obstetric parameters that decrease volume (V) or mononuclear cell content (MNC) do not influence total hematopoietic cell content (HSCC) in the cord blood (CB) harvest.

Beksac M., Dalva K., Arat M., Beksac S.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102, (Özet Bildiri) identifier

150. In vitro binding and complement dependent cytotoxicity (CDC) of Rituximab(R) in patients with chronic B-lymphoproliferative disorders: Effects of glycosylphosphatidil inositol (GIP) expression and cyclosporin A (CsA).

BEKSAÇ M., Dalva K., Akar G.
45th Annual Meeting of the American-Society-of-Hematology, SAN DIEGO, CALIFORNIA, 6 - 09 Aralık 2003, cilt.102, (Özet Bildiri) identifier

151. Moleküler belirleyici saptanmış akut lösemili olgularda yanıtın polimeraz zincir reaksiyonu PCR ve floresan in situ hibridizasyon FISH ile izlenmesi

YÜKSEL M., DALVA K., ARAT M., BEKSAÇ M.
XXX. Ulusal Hematoloji Kongresi, Türkiye, 10 - 12 Ekim 2003, (Özet Bildiri)

152. Long-term evaluation of hematopoietic and immune reconstitution following allogeneic peripheral blood hematopoietic cell transplantation during graft-versus-host disease

Dilek I., GÜRMAN G., Dalva K., BEKSAÇ M., Ilhan O., Ozcan M., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

153. Reduction of stem cell content is a feasible approach in standard risk HLA identical sibling allogeneic peripheral or marrow transplants

Arat M., Soydan E., Dalva K., Akan H., BEKSAÇ M.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

154. Comparative analysis of molecular response following interferon-alpha, imatinib mesilate or allogeneic stem cell transplantation (ASCT): best response is obtained with ASCT in chronic myeloid leukemia

BEKSAÇ M., Arat M., Dalva K., Ilhan O., TOPRAK S. K., GÜRMAN G., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

155. Kinetics of chimerism in sex-mismatched allogeneic hematopoietic cell transplantation with reduced-intensity conditioning

GÜRMAN G., Arat M., Soydan E., Dalva K., TOPRAK S. K., YÜKSEL M., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

156. The relation between T-helper subsets and the risk of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

Ozcan M., Topcuoglu P., BEKSAÇ M., Dalva K.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

157. Donor type epithelial cell repopulation in gastrointestinal mucosa following sex mismatch allogeneic peripheral blood transplantation: evidence for in vivo stem cell plasticity?

Kuzu I., Idilman R., Arat M., Dalva K., Soykan I., Akan H., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, (Özet Bildiri) identifier

158. Analysis of stem cell content and T-cell subsets in allogeneic peripheral stem cell harvest

Arslan O., Arat M., Ayyildiz E., Dalva K., Kabacam G., Tol M., et al.
29th Annual Meeting of the European Group for Blood and Marrow Transplantation/19th Meeting of the EBMT Nurses Group/2nd Meeting of the EBMT Data Management Group, İstanbul, Türkiye, 23 - 26 Mart 2003, cilt.31, (Özet Bildiri) identifier

159. Molecular response rates achieved in chronic myelogenous leukemia (CML) patients treated with interferon, imatinib mesylate (STI) or stem cell transplantation. A single institutional experience.

BEKSAÇ M., Arat M., Dalva K., Ilhan O., GÜRMAN G., Ozcan M., et al.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100, (Özet Bildiri) identifier

160. Preapheresis dendritic cell count predicts apheresis content in allogeneic PBSC collection.

Ilhan O., Arslan O., Arat M., Dalva K., Ayyildiz E.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100, (Özet Bildiri) identifier

161. Analysis of high and low risk chronic myeloid leukemia by gene expression profiling.

AKYERLİ BOYLU C., BEKSAÇ M., Holko M., Frevel M., Dalva K., GÜRMAN G., et al.
44th Annual Meeting of the American-Society-of-Hematology, PHILADELPHIA, PENNSYLVANIA, 6 - 10 Aralık 2002, cilt.100, (Özet Bildiri) identifier

162. Akut miyeloblastik lösemide indüksiyon sonrası toparlanma döneminde perifer CD34 düzeyinin prognostic önemi Bir pilot çalışma

ARAT M., TOPÇUOĞLU P., DALVA K., YÜKSEL M., soydan e., AKAN H.
XXIX. Ulusal Hematoloji Kongresi, Türkiye, 25 - 27 Ekim 2002

163. Telomeraz aktivitesinin malign plazma hücreleri ve eritroblastlar ile benign eritroblastlarda incelenmesi

YÜKSEL M., DALVA K., AKYERLİ BOYLU C., BEKSAÇ M.
XXIX. Ulusal Hematoloji Kongresi, Türkiye, 25 - 27 Ekim 2002
Kitaplar 4

1. Renal transplantasyon için HLA uyumunun değerlendirilmesi.

DALVA K.
Türkiye Klinikleri Üroloji - Özel Konular Renal Transplantasyon: Temel Konular, Cerrahi Süreç ve Transplant Takibi, Akbay Erdem, Editör, Türkiye Klinikleri, Ankara, ss.1-10, 2023

2. HLA ve Allojenik Nakil Özelinde HLA Sistemi

DALVA K.
HematoLog,, Hematopoietik Kök Hücre Nakli, Hayri Özsan, Muhit Özcan, Editör, Galenos, Ankara, ss.92-102, 2019

3. Akan Hücre Ölçer(Flow Cytometry) Genel prensipler

DALVA K.
Hematolog, Hematologlar için İmmunoloji, Tevfik Akoğlu, Cem Ar, Türkan Patıroğlu, Editör, Galenos, Ankara, ss.185-190, 2016

4. HLA typing with sequence-specific oligonucleotide primed PCR (PCR-SSO) and use of the Luminex™ technology.

DALVA K., BEKSAÇ M.
Bone Marrow and Stem Cell Transplantation,Methods in Molecular Biology, Meral Beksaç, Editör, HUMANA PRESS INC, 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA, Totowa, ss.87-99, 2014
Metrikler

Yayın

323

Yayın (WoS)

203

Yayın (Scopus)

130

Atıf (WoS)

1348

H-İndeks (WoS)

14

Atıf (Scopus)

1716

H-İndeks (Scopus)

17

Atıf (Scholar)

156

H-İndeks (Scholar)

6

Proje

13

Tez Danışmanlığı

1

Açık Erişim

15
BM Sürdürülebilir Kalkınma Amaçları